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CHAPTER 1 
GENERAL INTRODUCTION AND SCOPE OF THIS THESIS. 
It has long been recognized that only one-third of all women with disse-
minated cancer of the breast respond to endocrine therapy (surgical ablation, 
hormone additive therapy or the administration of hormone antagonists) (Hay-
ward, 1970; Stoll, 1970). A method of predicting a priori a breast cancer 
patient's response to endocrine therapy would greatly enhance the usefulness 
of endocrine therapy since 2 out of 3 women would be spared unnecessary 
endocrine measures (Jensen et al., 1967). In addition 2 out of 3 patients 
could receive alternative types of therapy earlier, which may be more benefi-
cial. A link between the hormone responsiveness of human breast cancer and 
the ability of such tumors to accumulate estrogen was discovered by Folce 
(1961). These investigators demonstrated that, following injection of tri-
tiated hexestrol, patients with breast cancer who responded favourably to 
adrenalectomy accumulated more radioactivity in their tumors than those 
patients who showed no improvement. 
During the past decade considerable insight has been gained concerning 
the mechanisms by which estradiol initiates specific phenotypic effects in 
target tissues. There is ample evidence that the initial step in estradiol 
action is the binding of the hormone to specific cytoplasmic receptor pro-
teins. Estradiol receptor proteins are present in target tissues such as 
uterus, vagina, anterior pituitary and mammary gland but are absent in non-
target tissues. The estradiol receptor is highly steroid specific and the 
estradiol receptor interaction is characterized by a very high affinity 
(K,~ 10 M). In the presence of estradiol, the receptor undergoes a 
temperature-promoted dimerisation with a second similar or dissimilar monomer 
to form the activated receptor complex (receptor transformation). The 
transformed complex migrates or translocates to the nucleus (receptor trans-
location), where it binds to acceptor sites in the chromatin. This inter-
action initiates a chain of events resulting in gene transcription and 
altered protein synthesis. For detailed information regarding the mechanism 
of action of steroid hormones, the reader is referred to recent reviews on 
this subject (Jensen and DeSombre, 1973; Gorski and Gannon, 1976; O'Malley 
and Birnbaumer, 1977; Yamomoto and Alberts, 1976). 
1 
Based on the premise that the estradiol receptor is a necessary re-
quirement for estradiol stimulation of tissue growth, Jensen et al. (1967) 
suggested that by measuring the uptake of tritiated estradiol by tumor tissue 
in vitro it might be possible to predict which patients will respond to endo-
crine treatment. It is now generally acknowledged that the estradiol receptor 
is useful in selecting patients for endocrine therapy. In several series 
about 60-75% of all breast cancers have found to contain measurable amounts 
of estradiol receptor. The collected data from a dozen centers around the 
world showed that 55-60% of the patients with estradiol receptor-positive 
tumors and only 8% of the patients with estradiol receptor-negative tumors 
responded to endocrine therapy (McGuire, Carbone and Vollmer, 1975). The 
estradiol receptor assay is therefore most useful in excluding patients with 
estradiol receptor-negative tumors from all types of endocrine therapy. 
However, about 40% of the patients with estradiol receptor-positive tumors 
fail to respond to endocrine therapy. 
Recently it has been emphasized that in endocrine unresponsive tumors, 
which contain cytoplasmic estradiol-receptors, there may be biochemical le-
sions distal to the initial binding step (Shyamala, 1972). Therefore,it may 
be preferable to measure an end product of estrogen action rather than the 
initial binding step. Because in normal estrogen target tissues the synthesis 
of progesterone receptor is dependent on and stimulated by estradiol, McGuire 
et al. (1975) hypothesized that the progesterone receptor could serve as a 
reliable marker of endocrine responsiveness of breast tumors. In other words, 
the presence of progesterone receptor in estradiol receptor-positive tumors 
would indicate that the tumors remained endocrine responsive. On the other 
hand, the response rate to endocrine therapy would be very low in tumors which 
contain estradiol receptor but no progesterone receptor. Moreover, progeste-
rone receptor bhould not be found in estradiol receptor-negative tvimors. 
This attractive hypothesis regarding the progesterone receptor as a reliable 
marker of endocrine responsiveness of breast tumors is currently under 
investigation in this as well as in various other laboratories. 
In Chapter 2, the dextran-coated charcoal assays developed for the 
measurement of estradiol and progesterone receptors are evaluated with 
special emphasis on reproducibility, specificity and the criteria used to 
classify tumors as receptor-positive or receptor-negative. As discussed 
earlier, patients will be excluded from all types of endocrine therapy on 
the basis of an estradiol receptor-negative tumor classification. 
2 
Therefore experimental conditions (e.g. cytosol dilution, cytosol protein 
concentration and interference of plasma protein contamination), which might 
have an influence on the classification of a tumor as receptor-positive or 
receptor-negative were carefully examined. In the literature there is only 
very limited information available regarding the intra- and inter-assay 
variation of the assays employed within a particular laboratory or regarding 
the assay variation between different laboratories. In this laboratory a 
tissue preparation was developed, which was used to study the inter-assay 
variation of the estradiol and progesterone receptor determinations and in 
addition seems suitable for inter-laboratory control studies. 
The experimental DMBA-tumor model has been most widely used in the study 
of mechanisms underlying hormone dependency of breast cancer (Leung, 1978). 
Tumor induction is carried out in female Sprague-Dawley rats by a single intra­
gastric feeding of 20 mg DMBA at the critical age of 50 days (Huggins et al., 
1961). Mammary tumors induced by DMBA administration are, just as human 
breast tumors, of ductal origin and have the histopathological features of 
adenocarcinomas (Sinha and Dao, 1975). About 60-90% of the tumors are re­
garded as hormone-dependent, since they regress after endocrine ablations, 
additive hormone treatments or the administration of hormone antagonists 
(Huggins et al., 1961; Pearson et al., 1972; Leung, 1978). This DMBA-tumor 
model has proved to be of value: a) for validation of new approaches and 
assays for the detection of hormone dependency. In fact King et al, 
(1965) and Mobbs (1966) used this animal model to demonstrate that hormone-
3 
dependent mammary tumors show a specific uptake of H-Ε in vivo, similar 
to that seen in normal estrogen target tissues. Moreover Jensen et al. (1967) 
reported for the first time that tissue slices of ovarian-dependent tumors 
3 
showed a greater incorporation of H-E„ than ovarian-independent tumors. 
b) for the selection and screening of new compounds with potential antitumor 
activity. For example the effects of antiestrogens and antiprolactin 
drugs on tumor growth have first been evaluated in this experimental tumor 
model before these compounds were subjected to clinical trials in advanced 
breast cancer (Heuson et al., 1976). с) for improving our knowledge of 
control mechanisms regulating tumor growth (Leung, 1978). Estrogens and pro­
lactin have shown to be of importance for the development and growth of 
DMBA-tumors (Bradley et al., 1976; Manni et'al., 1977; Leung, 1978). 
Estrogen exerts its influence on tumor growth by stimulating prolactin 
secretion by the pituitary and in addition estrogen and prolactin act 
3 
synergistically and directly at the tumor level. Studies with prolactin inhi-
bitors suggest that prolactin may not play as important a role in human 
breast cancer as in this animal model (European Breast Cancer Group, 1972). 
One of the difficulties with this DMBA-tumor model is that established 
tumors may undergo a spontaneous regression independent of the hormonal state 
of the animal, and hormone dependency may change with the age of the tumors 
(Young and Cowan, 1963; Griswald and Green, 1970). However, its major draw-
back is that tumors may invade local tissues but rarely, if ever, metasta-
size (Dao, 1964). 
In chapters 3 and A the results of studies performed with this tumor 
model are described, the objectives of which were: 1. to investigate whether 
responsiveness of DMBA-tumors to endocrine treatment (ovariectomy, estradiol 
administration and treatment with the antiestrogen tamoxifen) is related to 
quantitative ER levels; 2. to study whether the synthesis of the progeste-
rone receptor in these malignant tutnor cells, as in normal target tissues, is 
dependent on and stimulated by estradiol; and 3. to evaluate the hypothesis 
that the progesterone receptor is a·reliable marker of endocrine respon-
siveness of breast tumors. 
In chapter 5 the presence of estradiol and progesterone receptors in 
primary and metastatic human breast tumors has been studied. In particular 
conditions (such as menopausal status, contraceptive steroids, endocrine 
therapy and the stage of the disease) which night be of influence on the 
interpretation of these receptor data were analysed. 
The method evaluated in this thesis has been used in a collaborative 
clinical study described in the thesis of L.V.A. Beex (1979). This clinical 
study relates the estradiol receptor activity to results of treatment and 
to characteristics of the morbid history of the patients. 
4 

CHAPTER 2 
EVALUATION OF THE METHOD DEVELOPED FOR MEASUREMENT OF ESTRADIOL AND 
PROGESTERONE RECEPTOR BINDING SITES. 
2.1 Introduction 
During the past ten years a large number of procedures for the measure­
ment of cytoplasmic estradiol and progesterone receptors have been des­
cribed. All of these methods depend on occupation of the available binding 
sites by added labeled hormone, a binding which depends on the reversible 
formation of complexes between receptor proteins and radioactive steroid 
molecules. 
A variety of techniques are employed to separate the receptor-hormone complex 
from unbound hormone. The methods most commonly used are sucrose gradient 
centrifugation (Jensen et al., 1971; Wittliff, 1974), agargel electrophoresis 
(Wagner, 1978; Korstens, 1972) and dextran-coated charcoal separation 
(Korenman and Dukes, 1970; Feherty et al., 1971). Each of these methods has 
its own particular advantages and disadvantages (McGuire, Carbone and 
Vollmer, 1975) but in all of them the equilibrium between the reactants is 
ultimately lost, as one of the components is removed. Because of these non-
equilibrium conditions it is highly desirable to determine the number of 
binding sites by Scatchard analysis (Scatchard, 1949). An additional 
advantage of such an analysis is the possibility to monitor the specificity 
of each determination by calculating the apparent equilibrium dissociation 
constant. The dextran-coated charcoal assay is most suited for performing 
Scatchard analysis. Its major disadvantage is however the possible inter­
ference of plasma proteins with steroid binding to receptor binding sites. 
In the present study dextran-coated charcoal assays for the estradiol 
and progesterone receptors have been developed on a micro scale, allowing 
construction of a six-dose Scatchard plot even when relatively small 
amounts of tissue are available for analysis. As the radioactive ligand for 
3 the assay of ER, Η-estradiol was used. For the assay of PgR a radioactive 
3 
synthetic progestin H-R5020 was employed. As compared with progesterone 
itself, this compound hardly displays affinity towards corticosteroid 
binding globulin and dissociates less rapidly from progesterone receptor 
binding sites (Raynaud, 1977). 
6 
An extensive validation of the receptor assays developed, is presented 
in this chapter. 
2.2 Procedure 
2.2.1 Collection and storage of biopsy specimens 
Human tissue specimens were obtained through the cooperation from 
surgeons, internists and pathologists of the Canisius/WiIhelmina Hospital 
(Nijmegen) and the Radboud Hospital (Nijmegen). As far as macroscopically 
possible excised breast cancer tissue specimens were freed from fat, 
connective and necrotic tissue by the pathologist. A representative part 
was used for histological examination, the remaining tissue was immediately 
deep frozen (dry ice) and stored at -70 C. Within two weeks the tissue was 
transferred to our laboratory and stored in liquid nitrogen. Almost all 
metastatic biopsy specimens, after removal of a representative part for 
histological examination, were immediately placed on dry ice and within a 
few hours stored in liquid nitrogen. All biopsies were analysed within 2 to 
3 weeks after arrival at the laboratory. The excision and storage of DMBA-
tumor tissue will be described in chapter 3. 
2.2.2 Preparation of cytosols 
Frozen tissue was first pulverized in a stainless steel mortar immersed 
in liquid nitrogen. Thereafter the small pieces were vibrated for A5 sec at 
maximum frequency to a fine powder by means of a microdismembrator (Braun, 
Melsungen, Germany). The frozen tissue powder was transferred to a TenBroeck 
homogenizer and left to thaw on an ice bath. All subsequent steps were 
performed at 0 to A C. The tissue powder was homogenised in an appropriate 
volume of cold buffer. When enough tissue was available, 250 mg of tissue 
powder was weighed and 1.00 ml of buffer added, obtaining a w/v-ratio of 
1/4. The following buffers were used: 
TED-buffer: Tris-HCl 10 mM, EDTA 1.5 mM, DTT 0.5 mM, pH 7.4 for the determi-
nation of the estradiol receptor (McGuire at al., 1975). 
TEG-buffer: Tris-HCl 10 mM, EDTA 1.5 mM, a-monothioglycerol 10 mM, 10% 
glycerol (vol/vol) pH 7.4 for the determination of the progeste-
rone receptor (Rao et al., 1974). 
7 
When less than 250 mg tumor tissue was available a smaller w/v-ratio was 
chosen as for technical reasons at least 0.8 ml buffer was added to the pre­
pared tissue powder. The homogenate was centrifuged at 105,000 g for 60 min 
to prepare the cytosol, which was removed by pipetting. Care was taken to 
avoid contamination from the upper lipid layer. The prepared cytosol was 
always analysed without delay. 
2.2.3 Dextran-coated aharooal assay 
All receptor assays were performed in microtiterplates (v shape, 96 holes 
and maximum volume 250 μΐ) (Katzenellenbogen et al., 1973). Fig. 2.1 gives an 
outline of the procedure for the determination of cytoplasmic estradiol and 
progesterone receptor activity. To hole 1 and 2 buffer instead of cytosol was 
added serving as a control for the removal of free steroid by the dextran-
coated charcoal (DCC) suspension. With different batches of tracer the 
charcoal blank (blank) varied between 0.5 and 2.0% of the total amount of 
radioactive steroid (T) present. Hole 3 and 4 were used for determination of 
T. In a routine assay 50 |Л cytosol aliquots were incubated with six concen-
3 - 9 - 9 3 
trations of H-ligand ranging between 10 and 8.10 M for H-Ε and between 
_Q _Q О 
10 and 10 M for H-R5020. The sum of specific and nonspecific binding 
(B ) was determined in duplicate (hole 5 and 6). The binding in the presence 
of 10 M nonradioactive ligand, the nonspecific binding (B ), was determined 
at each H-ligand concentration (hole 7). The cytosol was preincubated with 
nonradioactive ligand 15 min prior to the addition of radioactive ligand. 
Radioactive ligand solutions were prepared shortly before use from a stock 
solution (10 M) stored at -20 С in ethanol. After evaporation of the ethanol 
3 
the H-ligand was dissolved in buffer containing 0.01% BSA. After incubation 
for 16-20 hours at 0 - 4 C, the unbound steroid was removed by adding 0.1 ml 
DCC-suspension. This suspension (0.25% Norit A and 0.025% dextran T 7 n in 
TED-buffer) was prepared and slowly stirred overnight at 0 - 4 С before each 
series of determinations. Eight 100 μΐ DCC-aliquots were added simultaneously 
by means of a multichannel pipettor. The plates were shaken for 10 min at 
0 - 4 С on a mechanical shaker and thereafter centrifuged for 20 min at 
1000 g to sediment the charcoal. Aliquots (0.1 ml) of the supernatants were 
transferred to counting vials containing 3.0 ml scintillation fluid. The 
radioactivity was counted with an efficiency of 46%. 
Fig. 2.1 Procedure for the assay of estradiol and progesterone receptors. 
Hole n o . a 1-2 3-4 5-6 
Buffer 55 ul 155 μΐ 5 μΐ 
Unlabeled steroid (10 M) - 5 μΐ 
Cytosol - - 50 μΐ 50 μΐ 
Preincubation 15 min at 
0 - 40C 
3H-steroidb 5 μΐ 5 μΐ 5 μΐ 5 μΐ 
Incubation 16 - 20 hr at 
0 - 40C 
Dextran-coated charcoal 100 μΐ - 100 μΐ 100 μΐ 
Vibrate the plates for 10 min at 0 - 4 С and centrifuge at 1,000 g for 20 min; 
take 100 yl aliquota for radioactivity counting. 
a 3 
For each of the six different Η-steroid concentrations 
b 3H-E 2: 1 - 8 nM and
 3H-R5020 : 1 - 10 nM. 
In those cases in which less than 200 mg tissue was available the cytosol 
volume obtained from 0.8 ml homogenate was in the order of 0.6 ml. Three 50 μΐ 
3 
cytosol aliquote were incubated with H-ligand (1.0, 2.0 and 8.0 nM), whereas 
3 
the nonspecific binding was determined only for the two highest H-ligand 
concentrations. Thus 600 μΐ cytosol was enough to determine the concentration 
of estradiol as well as progesterone receptor binding sites by a three point 
Scatchard analysis. 
2.2.4 Calculation of Receptor binding data 
All corrections and calculations were carried out by a programmable 
3 
Wang 600 calculator. For each H-ligand concentration the corresponding char­
coal blank was subtracted from the measured amounts of bound radioactivity. 
9 
These corrected values (В - blank = В' ; В - blank = В' ) were subtracted 
1 J. 1 N D IN о 
from the total amount of radioactivity present (T, hole 3 and 4), giving the 
corresponding amounts of unbound steroid (T - B' = F and Τ - Β' = Γν,ς)· 
The specific receptor binding (B ) was calculated according to the following 
equation (Chamness and McGuire, 1975) : 
B
S =
 B
'T - FT x B'NS / F N S 
It may be noted that the amount of nonspecifically bound ligand was calculated 
at the same free ligand concentration with which receptor bound ligand was in 
equilibrium (Rosenthal, 1967). This equation can only be used if the 
B ' / F -ratio is independent from the steroid concentration present. If this 
ratio was not constant the data were corrected graphically according to the 
method described by Rosenthal (1967). The calculated В -values were plotted 
against the corresponding Β
ς
/Γ ratio's giving the Scatchard plot. After 
calculation the line of best fit (least squares), the number of specific 
receptor binding sites (R) was determined from the intercept on the abscissa. 
The equilibrium dissociation constant (K.,) was calculated from the reverse 
of the slope of the straight line. The concentration of receptor binding 
sites was expressed as fmoles/mg protein. The protein content of each cytosol 
was determined by the method of Lowry (Lowry et al., 1951) using BSA as the 
standard. 
P,.3 Evaluation of receptor binding data 
2. 3.1 Scatchard analysis 
The specificity of each determination was monitored by performing 
Scatchard analysis. Various types of Scatchard plots were obtained. These 
types as well as the frequencies of their occurrence are shown in Fig. 2.2. 
In a vast majority of the tumors, classified as receptor-positive, linear 
plots (Fig. 2.2a) were observed. The remaining tumors, scored as receptor-
positive, showed linear portions in their plots from which low К -values 
could be calculated (Fig. 2.2b-e). The plot shown in Fig. 2.2b could reflect 
3 3 
H-ligand binding to at least two different binding proteins e.g. H - E 7 bound 
to its receptor and to Sex Hormone Binding Globuline (2.5.2). Scatchard plot 
type 2.2c could result from an overestimation of nonspecific binding. 
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Tumors classified as receptor-positive : 
ER 
PgR 
76·/. 
89"/. 
9.6 "V. 
3.4 "V. 
3.4»/o 
1.1°/. 
7.7°/. 
5.7°/. 
3.5°/. 
0.6°/. 
Tumors which do not 
allow interpretation : 
Tumors classified 
as receptor-negative: 
Fig. 2.2 Various types of Scatchard plots observed when human breast tumor 
oytosols were analysed for the presence of estradiol and progeste­
rone receptors. 
Similar Scatchard plots were obtained, when the nonspecific binding (B,,-) was 
determined in the presence of antiestrogens such as clomiphene and nafoxidine 
(5.10 M). These estrogen antagonists do not effectively compete for all 
estradiol receptor binding sites, because of the relatively low affinity 
compared to estradiol itself, resulting in an overestimation of nonspecific 
binding. The type of Scatchard plot in Fig. 2.2d was almost exclusively 
observed in tumor cytosols containing high receptor values. In these cases 
3 
the B/F ratios for the lowest H-ligand concentrations were greater than 
four. Several investigators have observed the type of non-linear Scatchard 
plot shown in Fig. 2.2e. It has been reported that the curvature at low 
3 . . . . 
H-ligand concentrations is perhaps due to 1. instability of unoccupied 
receptor sites (Chamness and McGuire, 1975) 2. positive cooperativity 
Π 
(Erdos et al., 1971) 3. inaccurate separation of free and bound ligand 
(Boeynaems and Dumont, 1975). In about 2% of all breast tumors analysed it 
was observed that the points do not fit a straight line, but were more or 
less scattered (Fig. 2.2f). Especially tumor cytosols with receptor values in 
the order of the lower limit of detection showed such Scatchard plots. It is 
obvious that the receptor concentration and the K.-value can not be calculated 
d 
from such data and these tumors could therefore not be classified and were 
excluded from the present study. Finally Fig. 2.2g gives an example of a 
receptor-negative tumor. 
An acknowledged advantage of Scatchard analysis is that an estimate of 
the dissociation constant (K,) is readily obtained, which should fall within 
a predicted range (McGuire, Carbone and Vollmer, 1975). The K,-values, calcu-
d 
lated from Scatchard plots with linear portions, ranged between 0.02 and 
9.0 nM for the estradiol receptor (0.60 + 0.65, n=270) and between 0.06 and 
10.0 nM for the progesterone receptor (1.0+^ 0.85, n=190). Fig. 2.3 shows the 
frequency distribution of K,-values for ER and PgR determinations in human 
d 
breast tumor cytosols. No normal distribution of K.-values was obtained. 
d 
Therefore a discrimination between receptor-positive and receptor-negative 
tumors on the basis of the K,-value could not be reached on usual statistical 
d 
terms. However К -values above A nM for ER and PgR do not belong to a con-d 
tinuous distribution. Therefore arbitrarily tumors with K,-values above 4 nM 
α 
were scored as receptor-negative. According to this strategy 2 tumors and 
8 tumors, that have been analysed for the presence of ER and PgR respectively 
(1-2% of all tumors) were classified as receptor-negative although their 
plots appeared to have a linear portion. 
2.0.2 Lower limit of sensitivity 
The lower limit of sensitivity was only roughly approached because, in 
this type of assay, not only the precision at low concentration determines 
this limit but additionally the arbitrarily chosen lower cutoff value for the 
К of the Scatchard plot plays a role. 
Another point of relevance is the often small size of the sample, which 
has to be analysed. The cytosol volume required to perform a complete 
3 
Scatchard analysis with 6 different concentrations of H-ligand is 0.9 ml. 
This volume is obtained from 250 mg tumor tissue, when the w/v-ratio is 1/4. 
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Fig. 2.3 Frequency distribution of К -rvalues for estradiol and progesterone 
receptor determination in human breast tumor aytosols. 
In 45% of the primary and 75% of the metastatic breast tumors analysed the 
available amount of tumor biopsy specimen was less than 250 mg. In these 
cases the w/v-ratio was smaller, resulting in a lower cytosol protein content. 
Therefore the relation between protein content and the receptor binding 
capacity was studied. The results of two representative experiments, perfor­
med with calf uterus cytosol, are collected in Tables 2.1 and 2.2. The 
undiluted uterine cytosol (w/v-ratio, 1/4) revealed an ER of 360 fmoles/mg 
protein. It can be seen from table 2.1 that a small decline of the concen­
tration of binding sites was observed at a 4-fold cytosol dilution, with a 
corresponding protein content of 1.4 mg/ml cytosol. Nevertheless at a 
16-fold dilution (0.35 mg protein/ml cytosol) the value measured was still 
83% of the receptor activity measured in the undiluted cytosol with a w/v-
ratio of 1/4. The actual amount of ER measured in this 16-fold diluted 
cytosol was 105 fmoles/ml cytosol. 
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Table 2.1 Influence of dilution of calf uterus cytosol on the measurement 
of ER binding sites. 
Dilution mg protein ER ER 
r- nil cytosol / * , < • , ,ч ,t , / · л 
factor ' (fmoles/ml cytosol) (fmoles/mg protein) 
2020 360 
1470 350 
980 350 
460 330 
220 315 
105 300 
Pulverized calf uterus tissue was homogenised with 4 volumes/g of tissue. The 
cytosol, prepared by centrifugation of the homogenate (w/v-ratio, 1/4), was 
diluted with different volumes of buffer and at each dilution incubated with 
3 
6 concentrations of H-Ε-, allowing Scatchard analysis. 
Table 2.2 Influence of dilution of calf uterus cytosol on the measurement 
of PgR binding sites. 
0 
1.3 
2 
4 
8 
16 
5.6 
4.2 
2.8 
1.4 
0.70 
0.35 
Dilution 
factor 
0 
1.3 
1.8 
2.25 
3 
9 
mg 
ml 
protein 
cytosol 
2.6 
2.0 
1.4 
1. 1 
0.85 
0.30 
(fmol 
PgR 
e s /ml 
1740 
1340 
880 
760 
600 
200 
cytosol) (fmol 
PgR 
es/mg protein) 
670 
670 
630 
690 
710 
670 
Calf uterus tissue was pulverized and homogenised in 4.0 ml buffer/g of tissue. 
The homogenate was centrifuged to obtain the cytosol. The cytosol (w/v-ratio, 
1/4) was diluted with different volumes of buffer and at each dilution in-
3 
cubated with 6 concentrations of H-R5020 allowing, Scatchard analysis. 
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Dilution 
factor 
0 
1.5 
2 
3 
6 
8 
10 
ms 
ml 
protein 
cytosol 
4.8 
3.2 
2.4 
1.6 
0.8 
0.6 
0.5 
(fmol 
ER 
Les/ml cytosol) 
500 
255 
185 
160 
90 
60 
45 
Table 2.3 Influence of dilution of human breast tumor cytosol on the 
measurement of ER binding sites. 
ER 
(fmoles/mg protein) 
105 
80 
75 
100 
115 
95 
95 
Human breast tumor cytosol (w/v-ratio, 1/4) was diluted with different volumes 
3 
of buffer and at each dilution incubated with 6 concentrations of H-E9, 
allowing Scatchard analysis. 
Table 2.4 Influence of dilution of human breast tumor cytosols on the 
measurement of ER binding sites. 
Dilution mg protein ER ER 
, ml cytosol ,, . , , ,. .,. , , . . 
factor (fmoles/ml cytosol) (fmoles/mg protein) 
55 9 
35 8 
0 0 
425 95 
310 100 
195 85 
85 75 
0 0 
Undiluted (w/v-ratio, 1/4) and diluted cytosols were incubated with 6 concen-
3 
trations of Η-estradiol, allowing Scatchard analysis. 
Cytosol A and Cytosol B. 
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o
a 
1.3 
2 
o
b 
1.5 
2 
4 
7 
6 
4.5 
3 
4.6 
3.05 
2.3 
1.1 
0.65 
Table 2.2 shows that dilution of calf uterus cytosol, up to a w/v-ratio of 
1/36 (0.3 mg protein/ml cytosol) had no systematic influence on the measured 
concentration of PgR binding sites ( 670 fmoles/mg protein). In addition, 
dilution of a human breast tumor cytosol did not have a marked influence on 
the amount of LR measured (Table 2.3). At a ten-fold dilution of the cytosol 
an ER value of 95 fmoles/mg protein (45 fmoles/ml cytosol) was measured, 
whereas in undiluted cytosol the value amounted to 105 fmoles/mg protein. 
In contrast to the foregoing observations it appeared from the following 
experiments, that dilution certainly can have pronounced etfects on the ER 
content measured. 
A calf uterus cytosol with a w/v-ratio of 1/4, containing ER in an amount 
of 315 fmoles/mg protein (3.2 mg protein/ml cytosol) was diluted 10-, 20- and 
30-fold. The linear Scatchard plots obtained (Fig. 2.4a,b,c), analysing the 
undiluted, 10- and 20-fold diluted cytosols, revealed a slight decrease of 
ER content from 315 to 290 and 250 fmoles/mg protein, respectively (K,-
values: 0.6, 1.3 and 1.6 nM). At the 30-fold dilution of the cytosol the 
Scatchard plot (Fig. 2.4d) did not rçveal the presence of high affinity 
binding sites any more. At the 20-fold dilution, that is the highest dilution 
m which high affinity binding sites were still present, the difference 
3 
between B„ and B.,„ was 70 for the lowest H-Ε- concentration (1.0 nM) and 
Γ NS 2 
190 coimts/2 mm/100 yl supernatant for the highest H-Ε concentration 
(8 0 nM). From this experiment it appeared that the lowest concentration of 
estradiol receptor binding sites, which still yielded an acceptable linear 
Scatchard plot - with a low K,-value - was 2 fmoles/50 yl cytosol or 40 
fmoles/ml cytosol. This value can be regarded as the lower limit of sensi­
tivity. At this extreme cytosol dilution (w/v-ratio, 1/80) the protein 
concentration of the cytosol was 0.16 mg/ml and therefore the lower limit 
of sensitivity expressed as fmoles per mg protein was calculated to be 250. 
The lowest estradiol receptor value - expressed as fmoles/mg protein -
actually measured in a cytosol of a human breast tumor was 2.4 fmoles/50 yl 
cytosol (Fig. 2.5a) or 48 fmoles/ml cytosol. This value approached the 
above mentioned lower limit of sensitivity very well. In this tumor cytosol 
the protein content was 9.8 mg/ml and therefore the lower limit of sensiti­
vity appeared to be 5 fmoles/mg protein. It appears that it has little sense 
to express the lower limit of sensitivity in fmoles/mg protein. Real infor­
mation is given when the expression fmoles/ml cytosol is used. 
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Fig. 2.4 A calf uterus cytosol with a w/u-ralio of 1/4 (3.2 mg protein/ml 
cytosol) was 10-, 20- and ¿0-fold diluted with buffer. The 
undiluted and diluted cytosols were incubated with 6 concentrations 
of H-estradiol3 allowing Scatdhard analysis. 
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Fig. 2.5 Lowest concentration of estradiol and progesterone receptor binding 
sites expressed as fnoles/mg protein actually measured in cytosols 
of different human breast tumors. The protein content of the 
cytosols used for the determination of ER and PgR were 9.8 and 
5.4 mg/ml cytosol respectively. 
For the progesterone receptor the lowest value measured in another tumor 
cytosol was 46 fmoles/ml cytosol (Fig. 2.5b) or 8 fmoles/mg protein. 
The effect of dilution of two different human breast tumor cytosols is 
shown in Table 2.A. In undiluted cytosol A an estradiol receptor concentra­
tion of 55 fmoles/ml cytosol (9 fmoles/mg protein) was measured. At a two­
fold dilution of this cytosol no high affinity binding sites were measurable. 
In this cytosol dilution resulted in a value of ER under the lower limit of 
sensitivity. It is noted that the protein content of the two-fold diluted 
cytosol was 3.0 mg/ml. The undiluted (w/v-ratio, 1/4) tumor cytosol В showed 
an ER value of 425 fmoles/ml cytosol (95 fmoles/mg protein). A four-fold 
dilution resulted in a slight decrease of the ER-value (75 fmoles/mg protein). 
At seven-fold dilution the Scatchard plot did not allow interpretation 
(see Fig. 2.2F). 
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From calculation it followed that the ER content of this cytosol had to be 
425/7 = 61 fmoles/ml cytosol and as such would remain detectable. Attention 
is drawn to the fact that the protein content of the cytosol was 0.65 mg/ml. 
It has been reported (Carola and McGuire, 1978; King et al., 1978) that ER 
measurements will be underestimated, when the protein content becomes lower 
than 1 mg/ml, an observation that was reconfirmed in the calf uterus cytosol 
dilution experiments described above (Table 2.1 and Fig. 2.4). 
Low protein concentrations were often observed in cytosols, when small 
human breast tumor biopsies were analysed. Actually in 7% of 403 tumors 
assayed for ER, the protein concentration was smaller than 2 mg/ml cytosol. 
It is noteworthy that when the frequency of ER-positive tumors was plotted 
as a function of the protein concentration of the cytosol (Fig. 2.6), a sharp 
decline was observed at protein values lower than 2 mg/ml. Actually the 
frequency of ER-positive tumors declined from about 70% to 40% when the 
protein concentration fell in the range of 1-2 mg/ml and to 0% for the 5 tumor 
cytosols, which had a protein concentration below 1 mg/ml. 
ΟΟη 
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39JZJ 
5 
24 ' 
7Θ 
65 
53 44 
1 
30 
- : 
<1 >1-2 >2-3>3-4>4-5>&6>6-7>7-θ >B 
•VoPgR- positive tumors 
B. Progesterone receptor 
32 
7 0 
6 4 5 
25 
«1 >1-2 >2-3>3-4>4-5>5-6>6-7>7-e > 8 
mg protein / ml cytosol 
Fig. 2.6 The relation between the frequency of EH- and PgR-positive human 
breast tumors and the protein concentration of the analysed ay to-
sole. The number of tumors assayed per group is indicated above 
the bars. 
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This decline of Che frequency of ER-positive tumors very likely resulted 
from the fact that the lower limit of sensitivity was reached and in addition 
because ER-assays become unreliable at low protein concentrations. 
Fig. 2.6b shows that the frequency of PgR-positive human breast tumors 
was not different for cytosols having a protein concentration above 2 mg/ml 
cytosol. Only 6 tumors were analysed with a protein content in the range of 
1-2 mg/ml and 3 tumors were classified as PgR-positive. Both tumor cytosols, 
which revealed a protein concentration below 1 mg/ml appeared to be PgR-
negative. 
2.4. Reproduaibi lity 
The intra-assay variation of both the estradiol receptor and the pro-
gesterone receptor assay was estimated in 2 experiments with calf uterus 
tissue. The results, collected in Table 2.5 show coefficients of variation 
of 2.2 - 3.5 and 7.5 - 10.3% respectively. The inter-assay variation (Table 
2.6) was analysed using both calf uterus and human breast tumor tissue. The 
coefficient of variation for the estradiol receptor assay was higher and 
amounted to 12.3 - 14.3%. The inter-assay variation coefficient for the 
progesterone receptor assay ranged between 8.1 - 12.3%. The inter-assay 
coefficient of variation appears to be not substantially different for these 
two target tissues containing receptor values ranging between 50 and 1000 
fmoles/mg protein. 
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Table 2.5 Intra-assay variation of the estradiol and progesterone receptor 
determination. 
Estradiol Receptor Progesterone Receptor 
number of determinations 5 7 5 7 
mean +_ SD (fmoles/mg protein) 91 + 3 630 +_ 14 210 + 16 1100 + 110 
coefficient of variation (Я) 3.5 2.2 7.5 10.3 
Calf uterus tissue was vibrated to a fine powder. Parts of this powder were 
homogenised in cold buffer and separately analysed for ER and PgR binding 
sites. 
Table 2.6 Inter-assay variation of the estradiol and progesterone receptor 
determination. 
Estradiol Receptor Progesterone Receptor 
Calf uterus tissue: 
number of determinations 11 21· 13 11 
mean + SD (fmoles/mg 330 + 40 630 + 80 810 + 87 1000 +_ 120 
protein) 
coefficient of variation (%) 12.3 12.6 10.7 12.3 
Human breast tumor tissue: 
number of determinations 7 9 6 
mean + SD (fmoles/mg 49 + 7 225 +_ 31 260 +_ 21 
protein) 
coefficient of variation (%) 14.3 13.8 8.1 
Tissue was pulverized in the frozen state and lyophilised in glass vials. The 
vials were stoppered whilst under vacuum and stored at 0 - 4 C. On various 
days lyophilised tissue was analysed for ER and PgR binding sites (see 2.7.3). 
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2.5 Specificity 
2.6.1 The steroid specificity of estradiol receptor binding sites 
The steroid specificity of estradiol receptor binding was established by 
3 
competition analysis, using H-Ε. as the radioactive ligand, and by direct 
binding studies using several radioactive estrogenic compounds. Competition 
3 
analysis was performed with one concentration of H-E- (5 nM) and increasing 
-9 -5 
concentrations of various nonradioactive compounds (4.10 - 4.10 M). It may 
be noted that all experiments were performed at 0 - 4 С and that the incu­
bation time was 1 8 - 2 0 hours. An example of the competition of several 
3 
estrogens or antiestrogens for H-Ε» binding to calf uterus is shown in 
Fig. 2.7. The results were expressed as relative binding affinities, accor­
ding to the method described by Korenman et al. (1970). The relative binding 
affinity is defined as the relative concentrations of competitor and radio-
3 
inert ligand required to displace 50% of bound H-ligand from specific 
receptor binding sites. The results' of a competition analysis, in which the 
steroid specificity of estradiol receptor present in three different target 
tissues was investigated, are collected in Table 2.7. The relative binding 
affinity for the binding to estradiol receptor sites present in calf uterus 
tissue and in DMBA-induced rat mammary tumor tissue was almost equal. The 
relative binding affinity for the binding sites present in biopsies of human 
breast tumors showed the same pattern, although in this particular experiment 
moxestrol and diethylstilbestrol were relatively strong competitors. The 
observation that progestins (R5020), androgens (DHT) and glucocorticoids 
(dexamethasone and Cortisol) did not compete, even when present at 1000-fold 
molar excess, indicates that the binding to this receptor is highly estrogen 
specific. In addition the potent synthetic estrogenic compounds mogtestrol 
3 
and diethylstilbestrol displaced H-Ε- most effectively, whereas estriol and 
17 α-estradiol were less active (Fig. 2.7). The antiestrogenic compounds 
nafoxidine and clomiphene competed only when present at high concentrations 
(Fig. 2.7). 
It has to be emphasized that the relative binding affinity estimated 
from competition experiments depends on: 
1. the incubation time and temperature (Bouton and Raynaud, 1978; Rochefort 
and Capony, 1977) 
2. metabolism during the incubation 
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Fig. 2.7 Competition for B-Er, binding in human breast timor aytosol. Tumor 
aytosol was incubated for 18 hr at 0 - 4 С with Ή-Ε- ( 6 nM) in 
the absence or presence of increasing concentrations of 17 ^-est­
radiol (17 ß-E ) , moxestrol (Mox), diethylstilbestrol (DES), 
estriol (E^), 17 a-estradiol (17 a-E-J, nafoxidine (Naf) and 
-9 -5 
clomiphene (clom), ranging between 4 χ 10 and 4 χ 10 M. 
3. the t rue competitor concentrat ion (adsorpt ion, s o l u b i l i t y ) (Capony and 
Rochefort, 1978; Nicholson et a l . , 1977) 
4. the presence of nonspecif ic binding p r o t e i n s (Capony and Rochefort, 1978; 
Nicholson et a l . , 1977). 
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Table 2.7 Competition for H-Estradiol binding in cytosol from calf uterus 
tissue, DMBA-induced mammary tumors and from human breast tumors. 
Competitor Calf uterus DMBA-mammary tumor human breast tumor 
Relative Binding Affinity (%)a 
Estradiol 
Moxestrol 
DiethylstiIbestrol 
Estriol 
17 α-Estradiol 
Nafoxidine 
Clomiphene 
R5020 
5 α-Dihydrotestos­
terone 
Dexamethasone 
Cortisol 
100 
70 
50 
6 
3 
0.4 
0.02 
<0.01 
<0.01 
<0.01 
<0.01 
100 100 
55 90 
40 80 
8 5 
4 2 
0.3 0.2 
0.04 0.02 
<0.01 <0.01 
<0.01 <0.01 
<0.01 <0.01 
<0.01 <0.01 
-9 3 Cytosol was incubated with 5.10 M Η-Estradiol in the presence of competing 
steroids (4.10 to 4.10"5M). 
Relative binding affinity is defined as the relative concentrations of 
competitor ап(Э radioinert ligand required to displace 50% of bound radio­
ligand from receptor binding sites. 
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Because of these influences the К -values of five estrogenic compounds 
were determined by competitive experiments using H-Ε. and also by direct 
binding studies using the radioactive forms of these compounds. The К -
3 . 3 
values of these experiments are collected in Table 2.8. Η-estradiol, H-
3 3 3 
ethynylestradiol, H-estnol, H-moxestrol and Η-estrone all showed linear 
Scatchard plots, after correction for nonspecific binding, revealing about 
the same concentration of specific binding sites (data not shown). From these 
direct binding studies it appeared that estradiol and ethynylestradiol have 
equal K,-values. The K.-values of estriol, moxestrol and estrone were 3.5, 
α d 
5 and 6 times higher. Competitive experiments revealed K,-values, which were 
equal to those obtained with direct binding studies only for estradiol. The 
K,-values obtained for ethynylestradiol, estriol and estrone, using competi-
3 
tive experiments with H-E , were 2 to 8.5-fold higher than those obtained 
in direct binding studies. The K,-value obtained for moxestrol however, using 
competitive experiments, was 4-times lower than the average K,-value obtained 
in the direct binding studies. Interestingly the direct binding studies 
3 
revealed that the nonspecific binding of H-ethynylestradiol was 3-fold 
3 
higher and the nonspecific binding of H-moxestrol was generally lower than 
3 
that of H-E. (2.5.2.5). From these observations it appeared that in competi-
. 3 . 
tive experiments with H-E» in the case of moxestrol the K, may be under­
estimated and thereby the affinity overscored, when compounds have a lower 
nonspecific binding than estradiol. On the other hand the K, in competitive 
d 
studies may be overestimated, when compounds have a higher nonspecific 
binding than estradiol (e.g. ethynylestradiol). 
2.5.2 Interference of plasma proteins with the assay of estradiol reoeptor 
binding sites 
Cytosol prepared from human breast tumor biopsies may be contaminated 
with plasma proteins. Plasma contains proteins which nonspecifically (albumin) 
or specifically (Sex Hormone Binding Globulin, SHBG) bind estradiol. SHBG 
binding sites, in contrast to albumin, can be saturated by 10 M estradiol. 
It has been reported that the albumin content of human breast tumor cytosols 
ranged from 3-52% of the total protein concentration (Maass et al., 1975; 
Teulings et al., 1975; Wagner and Jungblut, 1976; Netten et al., 1977), where­
as according to one study (Wagner and Jungblut, 1976) the SHBG concentration 
ranged between 100-710 fmoles/mg total protein. 
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Table 2.8 Comparison of the equilibrium dissociation constant (K,) of 
α 
estrogenic compounds for calf uterus receptor sites determined 
by direct binding studies or by competitive experiments with 
3 
JH-E . 
Compound Direct binding Studies Competition studies 
Κ,: 10~ M К,: 10~9M 
d d 
Estradiol 0.18+0.18 (7) 0.15 
Ethynylestradiol 0.14 (2) 1.2 
Estriol 0.61 (2) 1.5 
Moxestrol 0.90 + 0.49 (7) 0.20 
Estrone 1.05 (2) 2.2 
a . . . 3 
Calf uterus cytosol was incubated with six different concentrations of H-
ligand (1-8 nM) in the absence or presence of 10 M radioinert ligand. The 
K,-values were calculated from the slope of the Scatchard plot. The 
number of different determinations is indicated in parentheses. 
Increasing concentrations of H-E. (1-8 nM) were incubated in the absence 
or presence of two concentrations of nonradioactive competitor (10 and 
10 M). The K,-values were calculated from the slopes of double reciprocal 
plots, according to the following equation: slope H-E7 + competitor / 
3 l 
slope H-E. = 1 + competitor/K, competitor. The indicated K,-value for 
¿ d d 
each compound is the mean of the two values calculated for the two com-
petitor concentrations. 
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Therefore it was investigated whether plasma contamination seriously inter­
feres with the estradiol receptor assay as described under 2.2.3. 
2.5.2.2 Interference of albumin eontamination 
The interference of albumin with the assay of estradiol receptors was 
mimicked by the addition of albumin to calf uterus cytosol. The results of 
one of these experiments are shown in Table 2.9. In this experiment the 
albumin content ranged between 0 and 48% of the total protein content. The 
addition of increasing concentrations of albumin had no influence on the 
measurement of ER-binding sites in calf uterus cytosol. The ER-values 
ranged from 80-85 fmoles/mg calf uterus cytoplasmic protein. The measured 
K,-values however increased with the addition of albumin. 
α 
2.5.2.2 Interference of serum contamination 
Diluted human sera from two premenopausal women were added to calf uterus 
cytosol (Table 2.10). The concentration of ER binding sites of this cytosol 
was 185 fmoles/mg protein. The serum content of the prepared cytosols varied 
between 67 and 80%. As is indicated by the correlation coefficients (r » 
0.99) perfect linear Scatchard plots were obtained after correction for 
nonspecific binding with 10 M radioinert estradiol. Table 2.10 shows that 
even these high serum contaminations had no influence on the estimation of 
ER binding sites. The K,-values however again increased considerably by the 
addition of serum proteins. 
3 
Control studies of H-Ε. binding to these diluted sera revealed, that 
3 ¿ 
in this range of H-E9 concentrations (1-8 nM) the B/F ratio appeared to be 
constant (B/F = 0.04) and 70% of this binding appeared to be nonspecific 
(B/FV1C, = 0.028, results not shown). 
NS 
The SHBG level in plasma from pregnant women in the third trimester is 
about 3 to 4 times higher than in plasma of normal premenopausal women 
(Anderson et al., 1972). Therefore third trimester human pregnancy plasma 
was used to evaluate whether extensive SHBG contamination interferes with 
the estradiol receptor assay. 
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Table 2.9 Influence of the addition of albumin on the determination of 
estradiol receptor binding sites in calf uterus cytosol. 
Calf uterus cytosolic Albumin ER К 
protein (mg/ml) (mg/ml) (fmoles/ml cytosol) (nM) 
6.5 - 545 0.05 
6.5 2 530 0.08 
6.5 3 525 0.10 
6.5 4 540 0.11 
6.5 5 545 0.11 
6.5 6 545 0.12 
Calf uterus cytosol was analysed for ER, after the addition of increasing 
concentrations of BSA, 
Table 2.10 Influence of human serum proteins on the determination of 
estradiol receptor binding sites in calf uterus cytosol. 
Calf uterus protein Serum protein r ER К 
(mg/ml cytosol) (mg/ml cytosol) (fmoles/ml cytosol) (nM) 
5.7 - 0.982 1055 0.43 
4.3 8.6C 0.996 1085 1.02 
3.2 13.2° 0.995 1020 1.14 
4.3 8.9d 0.996 1090 1.08 
3.2 12.8d 0.995 1080 1.45 
8-fold diluted human serum of two premenopausal women was added to calf 
uterus cytosol. The resulting cytosols were analysed for ER-activity as 
described under 2.2.3. 
aAs a control 8-fold diluted human sera were incubated with H-E„ (1-8 nM) in 
—6 
the absence (в ) or presence (B,,,,,) of 10 M radioinert estradiol. v
 τ NS 
ь 
Least squares correlation coefficient 
cSerum of a premenopausal woman 
Serum of a premenopausal woman using oral contraceptives. 
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Five-fold diluted third trimester human pregnancy plasma was added to calf 
uterus cytosol and incubated with increasing concentration of H-Ε (Fig. 2.8), 
In this particular experiment the nonspecific binding was determined in the 
presence of 5 χ 10 M clomiphene. This antiestrogen, in contrast to estradiol, 
does not bind specifically to plasma proteins. The plasma protein content in 
this experiment was 74% of the total protein concentration. Saturation of 
specific estradiol receptor binding sites present in calf uterus cytosol was 
attained at approximately 2 nM (Fig. 2,8). 
Bound 3 H-E, (x10"9M) 
1.4 
0.2-
Calf uterus cytosol Calf uterus cytosol 
Human pregnancy plasma 
3H-Estrad¡ol concentration (xlO"9M) 
Fig. 2.8 Influenae of plasma proteins on the measurement of estradiol recep-
tor binding sites. Calf uterus cytosol and calf uterus cytosol plus 
five-fold diluted third trimester human pregnancy plasma was incu-
bated with increasing concentrations of H-E9 in the presence of 
S χ 10 M clomiphene. After 18 hr at 0 - 40C3 the amounts of total 
binding <*)j nonspecific binding (A) and specific binding (O) were 
determined by the DCC-assay. 
29 
Scatchard analysis of these data gave a linear plot with а К of 0.17 nM and 
d 
a binding capacity of 325 fmoles/mg protein. No saturation of binding sites 
was observed for the plasma contaminated cytosol. Clomiphene showed only a 
. . . 3 
minor competition for this H-E2 binding, indicating that almost all radio­
active ligand is bound to plasma proteins. Thus under conditions of extreme 
contamination of the cytosol with SHBG, binding of H-Ε to estradiol recep­
tor binding sites may become undetectable. 
3 
For comparison the binding of H-E» to pregnancy plasma was studied. 
Diluted pregnancy plasma (16 mg protein/ml) was incubated with estradiol con­
centrations, ranging between 1.0 and 10.000 nM (Fig. 2.9). The binding ulti­
mately was clearly saturable and again the B/F-ratio appeared to be constant 
in the concentration range from 1-8 nM. A decline of the B/F-ratio occurred, 
when the estradiol concentration amounted to 85 nM. After correction for non­
specific binding according to the method by Rosenthal (1967) a linear 
Scatchard plot (r = 0.98) was obtained with a K,-value of 60.10~9M. This К -
d d 
value was a t l e a s t 15 times higher than the K - v a l u e s observed in tumor 
d 
cytosols ( 2 . 3 . 1 ) . 
B/F 
0.5-
0 . 4 
0 . 3 
0 . 2 
0 . 1 
Bspec" ЗОООfmoles/mg protein 
K d : 6 0 x 1 C f 9 M 
• before "1 correction
 f o r 
о after ƒ nonspecific binding 
' ' ' Γ ­
ΙΟ 1 0 0 1000 10.000 
В (f m o l / 5 0 JU I di luted plasma) 
F-Lg. 2.9 Five-fold diluted third trimester human pregnancy plasma was incu­
bated with increasing estradiol concentrations ranging between 1.0 
and 10.000 nM. The Scatchard plot of total binding (·) was correc­
ted for nonspecific binding, accord'ng to Rosenthal (1967), to 
obtain the Scatchard plot of specific binding (O). 
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2.5.2.2 Stripping of estradiol bound to low affinity binding sites by dextran-
ooated oharooal 
The effect of stripping of H-Ε. bound to proteins of diluted human preg­
nancy plasma and to proteins of breast tumor cytosol during continuously 
shaking with dextran-coated charcoal is shown in Fig. 2.10. Under the condi­
tions chosen estradiol bound to plasma proteins dissociates very rapidly 
(t, = 1 0 - 1 5 min), whereas the dissociation of estradiol from its receptor 
appears to be very slow. Furthermore it was observed that within the normally 
used contact time of 10 min all estradiol previously bound dissociates from 
albumin (results not shown). Thus the binding of H-E„ to SHBG and to albumin 
is completely eliminated when a prolonged charcoal contact time of 90 min is 
used. Therefore the estimation of estradiol receptors with the normally used 
contact time of 10 min was compared with a contact time of 90 min. The re­
sults of these experiments, in which cytosols of calf uterus tissue and of 
human breast tumor biopsies were analysed, are collected in Fig. 2.11. 
•Vo Bound 
100-1 
ΘΟ 
6 0 
4 0 -
20-
breast t u m o r cytosol 
0
 specific binding 
plasma of pregnant women 
* 3 r d tr imester total binding 
% — o - o -
\ 
V 
1 1 1 1 
20 4 0 6 0 Θ0 100 
Charcoal contact t ime (min)at 0 - 4 "C 
Fig. 2.10 Cytosol of a human breast tumor (O) and S-fold diluted third tri­
mester human pregnancy plasma J·) were incubated with SH-E (5 nM) 
for 18 hr at 0 - 40C. After the addition of dextran-coated char­
coal the microtiter plates were continuously shaken for the indi­
cated times on a mechanical shaker. 
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The receptor values obtained a f t e r 90 min contact time general ly were lower 
than the corresponding values obtained a f t e r 10 min of charcoal t reatment . 
However, with the exception of one tumor the di f ferences were n e g l i g i b l e . 
(fmoles/mg protein) 
103-
102-
101-
; 
Estradiol receptor 
yo 
/o ° 
/ о 
/о 
κ. , 
/ 
1— ' 
ΙΟ
1
 ΙΟ'
1
 ίο-
3 
Charcoal contact t ime: lOmin ( fmoles/mg protein) 
Fig. 2.11 Influence of the dextran-coated ehavcoat contact Lime ση the 
estimation of ER binding sites in calf uterus tissue (η=7, · ) 
and in human breast tumor tissue (n=2Z, O). Cytosol was incubated 
in two miavotiter plates with 6 concentrations of Η-E .^ allowing 
Scatahard analysis. Free and weakly bowd steroid was removed by 
adding dextran-coated charcoal. One of the mtcrotiter plates was 
shaken for 10 and the other for 90 min. Seven tumor aytosols were 
regarded as estradiol receptor-negative with both procedures. 
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2.5.2.4 Nonspecific binding determined with cm excess cf estradiol, diethyl-
stilbestrol or moxestrol. 
Estrogens such as diethylstilbestrol (DES) of moxestrol (Roussel Uclafs 
compound R2858) show high affinity for estradiol receptor binding sites 
(2.5.2). These compounds, in contrast to estradiol, do not bind to specific 
plasma proteins (Raynaud et al., 1978; Wittliff, 1975). Therefore the 
difference in saturable binding using a large excess of radioinert estradiol 
compared to a large excess of DES (or moxestrol) represents estradiol binding 
to SHBG. To detect any SHBG interference the nonspecific binding in 49 human 
—6 —6 
breast tumor cytosols was determined with 10 M DES and 10 M E and in 27 
— fi —A Τ 
tumor biopsies with 10 M moxestrol and 10 M E,, using H-Ε, as the radio­
active ligand. The results of these experiments are collected in Fig. 2.12 
and 2.13. All tumors classified as estradiol receptor-negative using an excess 
of radioinert E- were also regarded as receptor-negative using DES (n=25) or 
moxestrol (n=12). For the tumors regarded as receptor-positive, it was ob­
served that the quantitative receptor values obtained after correction for 
nonspecific binding with Ε , were equal to or slightly exceeded the values 
using an excess of DES or moxestrol. This overestimation of ER binding sites 
using radioinert E- occurred only in tumors showing relatively low receptor 
concentrations. In these series of tumors the values obtained with radioinert 
E» never exceeded the receptor value obtained with DES or moxestrol more than 
40%. Two tumors revealed, after correction for nonspecific binding with E-, 
the type of nonlinear Scatchard plot illustrated in Fig. 2.2B. However the 
Scatchard plots of these tumors were linear after correction for nonspecific 
binding with DES and moxestrol respectively indicating that in these two 
tumors SHBG probably interfered with the assay of ER binding sites. 
2.5.2.5 Estimation of estradiol receptor binding sites assayed with estradiol 
and moxestrol as the radioactive ligands 
As was mentioned above and recently emphasized by Raynaud et al. (1978) 
H-moxestrol does not bind to SHBG. Under the conditions of our receptor assay 
method it appeared that this compound only showed a very low nonspecific 
3 binding even to human pregnancy plasma (ß/FNc = 0.02). Therefore H-moxestrol 
is particularly useful in the assay of ER binding sites present in human 
breast tumor cytosol, which may be contaminated with plasma proteins. 
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Estradiol receptor radioinert DES 
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Fig. 2.12 
Correlation between the 
concentration of specific 
estradiol receptor binding 
sites in 49 human breast 
tumor cytosols after eli­
mination of the nonspeci­
fic binding with 10 M 
radioinert E0 and with 
—6 10 M radioinert 
diethylstilbestrol. 
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Fig. 2.13 
Correlation between the 
concentration of specific 
estradiol receptor bin­
ding sites in 27 human 
breast tumor cytosols 
after elimination of the 
nonspecific binding with 
10 M radioinert E0 and 
-6 * • 
with 10 M radioinert 
moxestrol. 
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The correlation between ER binding sites assayed with H-moxestrol and with 
H-Ε in 65 human breast tumor biopsies can be seen in Fig. 2.14. Twenty 
tumors (39%) were regarded as receptor-negative and 39 tumors (60%) as 
receptor-positive using either radioactive ligand. The quantitative receptor 
values of these 39 tumors agreed very well (r = 0.96). The dissociation con­
stant for the moxestrol: receptor complex was 1.4 +_ 1.4 nM. 
Estradiol binding sites 
( tmoles/mg protein' 
101 1СГ ю-5 
Moxestrol binding sites (fmoles/mg protein) 
Fig. 2.14 Correlation betueen the oonaentration of estradiol receptor bin­
ding sites assayed with 3H-E2 (1-8 nM) and H-moxestrol (1-8 nM) 
in 65 human breast tumor aytosols. The nonspeaifia binding was 
determined in the presence of 10 M nonradioactive E and 
moxestrol respectively. Twenty tumors were regarded as receptor-
negative using both radioactive ligands. 
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The corresponding value for the estradiol: receptor complex in the same breast 
tumor cytosols was 0.40 +_ 0.30 nM. Furthermore it was observed that the non-
3 
specific binding was generally 2 times lower with H-moxestrol than with 
Η-estradiol. Attention is drawn to the fact that six tumors (9%) had to be 
3 
classified as receptor-positive using H ~ E 7 and
 a
s receptor-negative using 
moxestrol as the radioactive ligand. Although five of these tumors had low 
receptor values (<30 fmoles/mg protein), the observed K.-values of these 
tumors ranged between 0.22 and 3.5 nM, indicating that in these tumors est­
radiol was specifically bound to the receptor and not exclusively to SHBG. 
The observation that 4 of these 6 tumors revealed detectable amounts of PgR 
furthermore indicates that estradiol receptors are present in these tumors, 
because the synthesis of progesterone receptor is induced by estradiol 
(Wiest and Rao, 1971). Interestingly no tumors classified as receptor-
. . . 3 positive using H-moxestrol were estimated as receptor-negative using 
3 
H-estradiol. 
2.6 Specificity of the progesterone, receptor assay 
2.6.1 The synthetic progestins R5020 and Org 2058 as radioactive ligands for 
the progesterone receptor assay 
The assay of the cytoplasmic progesterone receptor has been seriously 
hampered by the fact that progesterone - besides to the receptor protein -
binds also tightly to certain plasma proteins as the corticosteroid binding 
globulin and to the glucocorticoid receptor. Furthermore progesterone 
dissociates very rapidly from its receptor binding sites (Milgrom et al., 
1972; Feil et al., 1972). It has been reported that a new synthetic pro-
3 
gestin, H-R5020 (Philibert and Raynaud, 1973) shows high affinity for 
progesterone receptor binding sites in normal progesterone target tissues 
such as uterus, pituitary, hypothalamus and in mammary tumor tissue 
(Horwitz and McGuire, 1975; Raynaud, 1977). This compound does hardly dis­
play affinity towards CBG and has the additional advantage that its complex 
with the progesterone receptor displays a much lower tendency to dissociate. 
3 
For these reasons H-R5020 was used as the radioactive ligand in the assay 
3 
of PgR. In this evaluation another synthetic progestin H-Org 2058 has been 
used, which also binds to the progesterone receptor with high affinity under 
formation of a slowly dissociating complex (Jänne et al., 1976). 
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The progesterone receptor sites of 72 human breast tumor specimens were 
estimated with R5020 and Org 2058 as the radioactive ligands. The results are 
presented in Fig. 2.15. Thirty tumors were regarded as receptor-negative with 
both radioactive ligands. The linear Scatchard plots of Al tumors revealed 
high affinity binding sites (K <4 nM) and were therefore classified as 
d 
receptor-positive. As can be derived from Fig. 2.15 no systematic difference 
between the quantitative receptor values was observed (r = 0.98). Only one 
3 
tumor was classified as receptor-positive using H-R5020 and as receptor-
3 3 3 
negative using H-Org 2058. The K,-values obtained with H-R5020 and H-Org d 
2058 were about the same: 0.90 + 0.80 and 0.80 + 0.70 nM respectively. 
Org 205Θ binding sites . 
(fmoles/mg protein) 
103-
^o
г
-
101-
ri '2 ' з 
IO1 IO2 IO3 
R 5020 binding sites (fmoles/mg protein) 
Fig. 2.15 Correlation between the aonoentration of progesterone receptor 
Ьгкаіпд sites assayed with 1-10 nM H-RS020 and H-Org 2058 in 
72 human breast timor eytosols. The nonspecific binding was 
determined in the presence of 10 nonradioactive R5020 and Org 
2058 respectively. Thirty tumors were regarded as receptor-
negative using both radioactive ligands. 
Human breast tumors 
У 
у 
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The same type of study was performed using 36 DMBA-induced rat mammary 
tumor biopsies. Eleven tumors were regarded as receptor-negative and 25 tumors 
as receptor-positive using both radioactive ligands. Again the quantitative 
3 3 
receptor values obtained with H-R5020 and H-Org 2058 agreed very well 
(r = 0.98). 
2.6.2 The steroid speaifioity of progesterone receptor binding sites 
The steroid specificity of PgR binding sites was studied with both 
3 
radioactive ligands. Fig. 2.16 shows the displacement of H-Org 2058 bound to 
human breast tumor cytosol with several nonradioactive competitors. It can 
be seen that Org 2058 and R5020 were approximately 10- to 20-fold more 
potent than the natural hormone progesterone. The anti-androgen cyproterone 
acetate and the synthetic glucocorticoid triamcinolone acitonide, both of 
which possess progestational activity, have a low displacing capacity. 
Estradiol and 5 a-dihydrotestosterone competed only when present in 
excessive amounts. Interestingly the glucocorticoids Cortisol and dexametha-
sone showed no competition when present at 1000-fold molar excess. Identical 
results were obtained when cytosols of human breast tumors were analysed 
with H-Org 2058 or H-R5020 (Table 2.11). This makes it highly probable that 
both ligands bind to the same receptor binding sites. 
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2.16 Competition for H-Org 2058 binding in oytosol from a human 
breast tumor. Tumor oytosol was inoubated for 18 hr at 0 - 4 С 
3 
with Η-Org P058 (7 nM) in the absence or presence of in­
creasing concentrations of Org 2068j RS020j medroxyprogesLerone 
aoetate (M.P.A.), progesterone (Prog.), cyproterone acetate 
(Cyp. Ac), triamcinole acetonide (Tr. Ac), 17 g-estradiol 
(17 ß-E ) , S a-dihydrote stoste rone (5 a-D.H.T. ) , dexametha-
-9 
sone (Dex.) and Cortisol, ranging between 4 χ 10 and 
4 χ 10~6M. 
3 3 
Table 2.11 Competition for Η-Org 2058 and H-R5020 binding in cytosols 
from human breast tumors. 
Competitor 
Org 2058 
R5020 
Medroxyprogesterone acetate 
Progesterone 
Cyproterone acetate 
Triamcinolone acetonide 
Estradiol 
5 a-dihydrotestosterone 
Cortisol 
Dexamethasone 
3H-0rg 2058 
100 
60 
30 
5 
3 
0.7 
0.04 
0.04 
<0.01 
<0.01 
3H-R5020 
100 
50 
30 
5 
3 
0. 
0. 
0. 
<0. 
<0. 
,8 
04 
04 
01 
01 
3 
Human breast tumor cytosol was incubated with 8 nM H-Org 2058 and 8 nM 
3 9 
H-R5020 in the absence or presence of increasing concentrations (4.10 to 
4.10 M) of various nonradioactive competitors. The results were expressed 
as the relative binding affinity, which is defined as the relative concen­
tration of competitor and radioinert ligand required to displace 50% of 
bound radioligand from its receptor binding sites. The relative binding 
affinity of Org 2058 was taken to be 100. 
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2.6.3 Interference of gluaoaortiooid receptor proteins 
It has been demonstrated that R5020 besides to the progesterone receptor 
binds also to the glucocorticoid receptor, albeit with low affinity (Raynaud, 
1977). Lippman et al. (1977) estimated a K.-value of 20 nM for the binding of 
R5020 to glucocorticoid receptors and emphasized, that the use of R5020 could 
lead to an overestimation of the concentration of high affinity PgR binding 
sites, when glucocorticoid receptors are present. Therefore it was investi­
gated whether the presence of glucocorticoid receptors interferes with our 
progesterone receptor assay. 
Rat liver, which contains high concentrations of glucocorticoid recep­
tors, was used to study the binding properties of R5020 and Org 2058 to 
these receptors. Rat liver cytosol was incubated with H-dexamethasone and 
increasing concentrations of radioinert R5020 or Org 2058 (10-40.000 nM) 
and dexamethasone. These displacement studies revealed that R5020 as a 
competitor was about 30 times less potent (Relative Binding Affinity : 3.5) 
than dexamethasone. Org 2058 however competed only weakly for these 
receptor binding sites (Relative Binding Affinity : 0.12). Direct binding 
3 3 3 
studies of H-dexamethasone, H-R5020 and H-Org 2058 to rat liver 
cytosol showed that only dexamethasone was bound with high affinity. After 
correction for nonspecific binding a straight Scatchard plot was obtained 
-9 
with a K, of 3.5x10 M and the concentration of specific dexamethasone 
3 3 
binding sites was 375 fmoles/mg protein. H-R5020 and H-Org 2058 however 
only demonstrated nonsaturable binding (B = 0.05). The direct inter­
ference of glucocorticoid receptors with the determination of progesterone 
receptors was mimicked by addition of rat liver cytosol to calf uterus 
cytosol. In these studies progesterone receptor sites were determined with 
3 
H-R5020, because the displacement studies indicated that interference can 
only be expected, when the receptor assay is performed with this radio­
active ligand. The results of these experiments are summarized in Table 
2.12. After correction for nonspecific binding, linear Scatchard plots 
were obtained (r = 0.98-0.99, Table 2.12) suggesting that R5020 was 
bound to a single class of binding sites. The addition of liver cytosol 
caused no or only a slight increase in the concentration of receptor 
binding sites, whereas the К -value remained the same. 
d 
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K d
-9 (10 *M) 
1.6 
1.4 
1.5 
1.6 
Receptor 
sites 
545 
605 
580 
560 
Table 2.12 Analysis of interference of glucocorticoid receptors with the 
assay of progesterone receptor binding sites using R5020 as the 
radioactive ligand. 
Calf uterus cytosol Rat liver cytosol r 
(mg protein/ml incubate) 
5.2 - 0.99 
5.2 1.2 0.98 
5.2 2.4 0.99 
5.2 4.8 0.99 
Different dilutions of rat liver cytosol were added to a constant volume of 
calf uterus cytosol. Progesterone receptor binding sites were determined 
3 
with H-R5020 as previously described (2.2.3). 
a . . 3 
Rat liver cytosol was incubated with H-Dexamethasone in the absence or 
presence of 10 M radioinert dexamethasone. Scatchard analysis revealed 
a K, of 1.0 nM and the concentration of receptor sites was 305 fmoles/ 
mg protein. 
Least squares correlation coefficient. 
с "fmoles/mg calf uterus cytoplasmic protein. 
2.6.4 Stripping of radioactive ligand by dextrcm-coated aharaoal 
The determination of receptor binding sites as performed in the present 
study, using charcoal for separation of free and bound steroid, occurs 
under non-equilibrium conditions. This implies that only tritiated ligands 
may be used, which dissociate slowly from the receptor binding sites. The 
3 3 
dissociation of bound H-R5020 and H-Org 2058 to human breast Lumor cytosol 
during continuously shaking with DCC (0 - 90 min) showed bifasic curves. 
A steep fall was observed during the first 10 min, probably representing 
stripping of low affinity binding. 
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Between 20 and 90 min the decrease in radioactivity became relatively slow, 
probably due to dissociation of these progestins from the specific recep­
tor binding sites. The dissociation rate constants (20 - 90 min) were 
-4 -4 -1 
calculated to be 0.61 χ 10 and 0.69 χ 10 s for R5020 and Org 2058 
respectively. From these rate constants it follows that during the normally 
3 
used contact time of 10 m m the dissociation of specifically bound H-ligand 
is less than 5%. 
2.7 The effect of storage of target tissue on oytoplasmio receptor binding 
sites 
2. 7.1 Storage of DMBA-induced rat mammary tumor tissue at -70 С 
DMBA-induced mammary tumor tissues were analysed for ER- and PgR-binding 
sites before and after storage for 15 months in a Reveo Ultra Deepfreezer 
(-70 C). Before storage the ER levels ranged between 25 and 225 fmoles/mg 
protein, and after storage the ER levels in all tumors (n=ll) had decreased 
and now ranged between 15 and 85 fmoles/mg protein. The average decrease 
was 50%. The PgR-levels before storage ranged between 75 and 230 fmoles/mg 
protein and became undetectable in all tumors (n=6) under these storage 
conditions. Thus it appears that both ER and PgR proteins deteriorate during 
prolonged storage at -70 C, but estradiol receptor proteins resist these 
conditions better than progesterone receptor proteins. 
2.7.2 Storage of human breast timor specimens in liquid nitrogen 
Residue tumor specimens were re-analysed after varying storage periods 
in liquid nitrogen ranging between 2 and 18 months. Before storage the ER 
levels ranged between 16 and 606 fmoles/mg protein. In 16 of 17 tumors 
analysed the quantitative values observed after storage in liquid nitrogen 
were not different from the corresponding values measured before. The 
remaining tumor had an ER value of 60 fmoles/mg protein and showed no 
ER binding 14 months later. In 14 tumors PgR levels were determined before 
and after storage in liquid nitrogen. Before storage the values ranged 
between 70 and 1120 fmoles/mg protein. After storage 4 tumors showed no 
PgR binding, in 3 tumors the levels had declined 50% or more and in 7 
tumors the levels did not change. 
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These observaLions indícate that, as far as the progesterone receptor is 
concerned, in some tumors receptor activity is not fully preserved even under 
conditions of this very low temperature. 
2.7. 3 Storage of lyophilised target tissues; a standard preparation suitable 
for interlaboratory quality control 
Comparison of assay techniques of different laboratories has not been 
without difficulty because of the lability of receptor proteins upon storage 
(2.7.1 and 2.7.2) and the heterogeneity of breast tumor specimens (Rao and 
Meyer, 1977). Therefore the effect of lyophilisation and subsequent storage 
at 4 С or at room temperature on ER- and PgR-binding sites of a number of 
target tissues was investigated. The results were recently published (Koenders 
et al., 1978) and can be summarized as follows: 
- during lyophilisation of DMBA-induced rat mammary tumor tissues, human 
breast tumor tissues and calf uterus tissues no deterioration of ER and 
PgR occurred. 
- lyophilisation did not influence dissociation constants (K.) or steroid 
d 
specificities of ER and PgR binding sites. 
- no loss of ER and PgR was observed when lyophilised calf uterus tissue 
was stored for 5 months at 0 - А С (Fig. 2.17) and for 3 weeks at room 
temperature. 
Recently the effect of storage of lyophilised human breast tumor 
tissue was investigated. It appeared that no or only a minor decrease 
of ER binding sites occurred during storage at 0 - 4 С for 4 months or at 
room temperature for at least nine days. During storage of this tissue at 
0 - 4 С no loss of PgR was observed during the first 35 days. Thereafter 
the PgR binding declined slowly (tí = 30 days). Storage of this tissue at 
2 
room temperature showed that after 28 days the PgR level had decreased 60%. 
44 
f moles/ mg protein 
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Fig. 2.17 Fulverized aalf uterus tissue was lyophilised in glass vials and 
stored at 0 - 4 C. On various days lyophilised tissue powder has 
been analysed for the presence of ER and PgR. 
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2.8 Discussion 
It is generally accepted that patients with estradiol receptor-negative 
metastatic breast tumors have a poor chance to respond to endocrine therapy. 
Currently, in many clinics, when a tumor has been assayed as estradiol 
receptor-negative, the patients are excluded from endocrine treatment and 
are subjected to chemotherapy. 
It is obvious, that when a negative result of an assay has such far 
reaching consequences, the laboratory has a need for explicit criteria by 
which a tumor can be labeled as receptor-positive or receptor-negative. 
In this chapter attention has been paid to the evaluation of the 
receptor binding data especially at the lower limit of sensitivity (2.3.2). 
Especially at this detection limit Scatchard analysis is highly useful to 
distinguish receptor-positive and receptor-negative tumors. From the 
Scatchard plot it can be derived whether high affinity binding sites 
(K,<A nM) are present. 
d 
In this study the lowest receptor values actually measured in human 
breast tumor cytosols were 5 and 8 fmoles/mg protein for ER and PgR 
respectively. From cytosol dilution experiments (2.3.2) it appeared that 
ER values became underestimated, when the protein concentration becomes 
smaller than 2 mg/ml cytosol. It has been shown that below this protein 
concentration human breast tumor cytosols may even be falsely scored as 
ER-negative (Table 2.A). Therefore it may be recommended in the case of 
receptor-negative tumors to add information about the protein content of 
the cytosol. Actually a sharp decline in the incidence of ER-positive 
tumors was observed when the protein concentration of the cytosol was 
smaller than 2 mg/ml. 
It has been suggested that the estradiol receptor level may be 
overestimated in the presence of contaminating Sex Hormone Binding Globulin 
(SHBG) (Ratajczak and Hähne1, 1976; Sherman and Miller, 1976; Raynaud et al., 
1978). Whether SHBG actually interferes with the estradiol receptor assays, 
performed in human breast tumors, has been evaluated (2.5.2). Estrogenic 
compounds such as diethylstilbestrol or moxestrol, have a high affinity 
for the estradiol receptor (2.5.1) but hardly bind to SHBG. Therefore these 
compounds have been used for the assessment of nonspecific binding and 
the results were compared with those obtained using excess of radioinert 
estradiol itself (2.5.2.4). 
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It appeared that, if present, the interference was slight and occurred only 
in tumors showing relatively low receptor concentrations. This finding was 
3 
to a large extent confirmed in experiments m which H-moxestrol was used as 
the radioactive ligand and in experiments in which the contact time of the 
cytosol with dextran-coated charcoal was increased from 10 to 90 min. Okret 
et al. (1978) developed an isoelectric focusing assay in which ER and SHBG 
proteins are separated. They concluded that the degree of serum contamina­
tion in tumor specimens obtained as surgical biopsies does not interfere 
3 
with the assay of ER. Furthermore these investigators concluded that H-
moxestrol eliminates SHBG interference when in tissue specimens, such as 
collected by fine needle aspiration, excessive serum contaminations were 
present. Another group of investigators, for other reasons, also recommended 
3 
the use of H-moxestrol as the radioactive ligand in the assay of ER in 
human breast tumors (Raynaud et al., 1978). Raynaud et al. (1978) observed 
. . . 3 
that several tumors were receptor-positive using H-Ε. and receptor-negative 
3 
using H-moxestrol and concluded that these tumors could \η fact be merely 
contaminated by plasma. It has to be emphasized however, that in A out of 6 
tumors which in our study had to be classified as receptor-positive using 
3 3 
H-Ε and as receptor-negative using H-moxestrol, progesterone receptor 
activity was present. This finding strongly indicates that the ER binding 
sites measured do not represent SHBG interference. 
The steroid specificity of estradiol receptor binding sites was 
3 
established by competition analysis, using H-Ε- as the radioactive ligand, 
and by direct binding studies using several radioactive estrogenic com­
pounds (2.5.1). Interestingly, remarkably discrepancies were observed 
between the К -values obtained by direct binding studies as compared to 
those obtained by competitive experiments. These results are in accordance 
with those reported by Rochefort and Capony (1977), Nicholson et al. (1977), 
Capony and Rochefort (1978) and Okey and Bondey (1978) for several other 
estrogenic and antiestrogenic compounds. 
In this as well as in several other studies it was observed that Κ ­
α 
values for steroid hormone receptor complexes show a wide range, when human 
breast tumors are analysed (Braunsberg et al., 1975; Leclercq et al., 1973). 
The determination of the K,-values in these type of assays occurs under 
d 
non-equilibrium conditions. 
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Under these conditions, in which tracer is stripped from low affinity binding 
sites (2.5.2.3), the free ligand concentration is overestimated giving 
Scatchard plots in which the slope becomes less steep, whereas the intercept 
on the abscissa is correct (Blondeau and Robel, 1975). This may explain why 
the addition of albumin or serum proteins to a calf uterus cytosol (2.5.2) 
increased the К -values, but had no influence on the estimation of ER binding 
α 
sites. 
3 
For the assay of PgR a synthetic progestin, H-R5020, was used as the 
radioactive ligand. This compound was recommended because it has high 
affinity for the progesterone receptor and hardly binds to CBG (Raynaud, 
1977). In addition its complex with the progesterone receptor dissociates 
more slowly as compared to progesterone itself. The assay for PgR was 
evaluated by comparing the results obtained with this ligand and those 
3 
obtained using another synthetic progestin, H-Org 2058. It has been re­
ported that Org 2058 binds to plasma proteins to a lower extent than R5020 
(Jänne et al., 1976)· The PgR values actually measured with either radio-
active ligand did not show systematic differences. This finding does not 
support the suggestion of Seematter et al. (1978) that R5020 binding to 
human serum albumin interferes with the assay of PgR. 
When estradiol receptor assays were introduced in 1971 it was believed 
adequate to distinguish between receptor-positive and receptor-negative 
tumor specimens (Jensen et al., 1971). From the first reports it appeared 
that approximately 50Z of the breast tumors contained specific estradiol 
receptors (Wittliff, 1974). However since that time the reported incidence 
of ER-positive tumors has risen to even as high as 70-85% (McGuire, Carbone 
and Vollmer, 1975). This rise has been attributed to increased sensitivity 
of the methods employed. Several recent studies have suggested that 
quantitative ER values can be used to distinguish between patients^ which 
have a high or a low probability in obtaining a remission to endocrine 
therapy (DeSombre and Jensen, 1977; Engelsman, 1978). Because there is 
considerable variation between different assay methods and values obtained, 
there is a serious need for inter-laboratory quality control. 
Recently for the ER assay a quality control study has been reported 
(King et al., 1978). In this study frozen breast tumor pieces have been 
used. It appeared that, although most laboratories with a few exceptions 
agreed whether a tissue specimen was ER-positive or ER-negative, remarkable 
differences in quantitative ER levels were obtained. 
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These differences were apparently related to the method of homogenisation, 
the presence or absence of thiol reagens and tumor heterogeneity. 
In the present study it was shown that the ER and PgR levels of target 
tissues were not influenced by lyophilisation (2.7.3). Lyophilised tissues 
can be stored at 0 - 4 С for at least one month without loss of receptor 
activity. Even storage performed at room temperature for 1-2 weeks showed 
no or only a minor decrease of ER and PgR binding sites. Therefore lyophi­
lised tissue powder seems suitable for inter-laboratory quality control 
studies. 
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CHAPTER 3 
ESTRADIOL AND PROGESTERONE RECEPTORS IN DMBA-INDUCED MAMMARY TUMORS BEFORE AND 
AFTER OVARIECTOMY AND AFTER SUBSEQUENT ESTRADIOL ADMINISTRATION. 
3.1 Introduction 
Breast cancers induced in rats by the administration of a polycyclic 
aromatic hydrocarbon 7,12-dimethyl benzanthracene (DMBA) often show striking 
growth responses to endocrine ablations and additive hormone treatment 
(Huggins and Yang, 1962; Griswold and Green, 1970; Pearson et al., 1972). The 
presence of estradiol receptors in these experimental tumors has been well 
documented (Terenius, 1968; McGuire and Julian, 1971; Leclercq and Heuson, 
1973). Some authors claimed that estradiol receptor binding sites were selec-
tively present in tumors which regressed after ovariectomy (McGuire and Julian, 
1971; Nomura et al., 1974). More recently it has been reported that essen-
tially all DMBA-tumors, ovarian-dependent as well as ovarian-independent, 
contain estradiol receptors (Boylan and Wittliff, 1975; DeSombre et al., 1976). 
In a small number of studies it has been attempted to relate the level of 
estradiol receptors to the responsiveness to ovariectomy of DMBA-tumors (Mobbs 
and Johnson, 1974; DeSombre et al., 1976). Although ER levels in ovarian-
independent tumors tended to be lower than those in overian-dependent tumors, 
there was considerable overlap between the corresponding values obtained in 
the two groups of tumors. 
It has been hypothesized by McGuire et al. (1975) that for the prediction 
of endocrine responsiveness of breast tumors, the progesterone receptor -
being an end product of estrogen action - would be a better marker than the 
estradiol receptor which, according to these authors, is only involved in the 
initial step in estrogen action. 
In the present study the relation between ER levels and endocrine res-
ponsiveness was re-examined. Furthermore it was analysed whether measurement 
of the progesterone receptor would give more reliable information about 
hormone-dependency of DMBA-tumors. 
Finally the present study analyses whether estradiol - as in normal 
target tissues - exerts control over the production of the progesterone recep-
tor in DMBA-tumors. 
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3.2 Experimental Procedures 
3.2.1 Mammary tumor induction 
Mammary tumors were induced in 50 days old female Sprague-Dawley rats by 
a single intragastric feeding of 20 mg DMBA in 1.0 ml sesame oil (Huggins et 
al., 1961) . The animals used for the first experiment (described in this 
chapter) were obtained from the Zentralinstitut für Versuchstierzucht, 
Hannover/Linden (W. Germany). In the first two weeks after DMBA-administration 
15% (9/60) of the animals died. Autopsy revealed similar abnormalities as 
described by Huggins and Morii (1961) and Dao (1964) e.g. leukopenia, 
diminished food intake, gastrointestinal tract bleeding, degenerative 
changes in liver, kidney and lymph nodes and enlarged adrenals, which were 
dark red in color. Huggins and Dao observed necrosis and hemorrhage of the 
adrenals and attributed the sudden death of these animals to adrenal apoplexy. 
The first mammary tumors were detected in the seventh week after DMBA-admini-
stration (Fig. 3.1). Thereafter all .animals rapidly obtained mammary tumors 
and at day 58 each animal had at least one mammary tumor. The average number 
of tumors per animal reached a maximum of about 7, 120 days after DMBA-admi-
nistration (Fig. 3.2). Some animals obtained as many as 10 tumors. 
3.2.2 Assessment of mammary tumor growth and excision of tissue biopsies 
Tumor areas of all tumors of each animal were calculated at least once 
every week from caliper measurements of two diameters at right angles (length 
χ width; sq cm). The diameter of a tumor had to be about 0.7 cm (0.5 sq cm) in 
order to be precisely measured. When the first tumor reached an area of about 
4 sq cm a small biopsy (0.5 - 1.0 g) was taken at random stages of the oestrus 
cycle under light ether anesthesia. As a consequence of this procedure, tumors 
were selected. Tumors with a very slow growth rate, tumors which remained 
small and tumors which developed after a long time were not included in the 
receptor studies. The excised biopsy specimen was washed in cold saline and 
trimmed of fat, connective tissue and necrotic tumor areas. The biopsy was 
cut into small pieces and a representative section was removed for histolo­
gical examination. All tumors included in the receptor studies were classi­
fied as adenocarcinomas (Dr. K. Kubàt, Department of Pathology, University of 
Nijmegen). 
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Figs. 3.1 and 2.2 Induction of mammary tumors in female Sprague-Dawley rats 
following a single feeding of 20 mg DMBA, 
Fig. 3. 1 
Fig. 3. 2 
Tumor incidence as a function of time after DMBA-admini-
stration. 
Average tumor number per animal as a function of time after 
DMBA-administration. 
• Sprague-Dauley rats; W. Germany (Chapter ¿) 
• О Sprague-Dawley rats; France (Chapter 4). 
The specimens were immediately frozen in liquid nitrogen and stored at -70 С 
in a Reveo Ultra Deepfreezer. When tumors regained prebiopsy size, the 
animals were bilaterally ovariectomized under light ether anesthesia. After 
the effect of this treatment on the tumor growth was assessed a second 
biopsy was taken from the same tumor already biopsied before. The rate of 
tumor regression after the removal was generally very rapid and the biopsies 
were on the average excised 10 days after ovariectomy. Ovariectomized animals 
with regressed tumors subsequently received 5 i^g estradiol as the benzoate 
(s.c.) daily. After the tumor growth response to estradiol administration was 
established the animals were sacrificed and the tumors were excised 24 hours 
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after the last estradiol injection. 
3. 2. 3 Classification of marmary tumors 
Fig. 3.3 shows examples of tumor types in respect to their responsiveness 
to ovariectomy and the subsequent replacement of estrogen, which were included 
in the receptor studies. Four major types of tumors were obtained: 
1. Ovarian-independent tumors, which continued to grow after ovariectomy 
(Fig. 3.3a). 
2. Ovarian-dependent tumors, which regressed at least 25% within 10 days after 
ovariectomy (Fig. 3.3b). Of all growing tumors 86% (55/64) were scored as 
ovarian-dependent and 14% (9/64) as ovarian-independent. 
3. Estradiol-responsive tumors, which regressed after ovariectomy and regrew 
after subsequent estradiol administration (Fig. 3.3c). 
4. Estradiol-unresponsive tumors, which regressed after ovariectomy, but did 
not regrow after estradiol administration. In some of these tumors regres-
sion stopped, when estradiol was administered, whereas in others regression 
continued (Fig. 3.3d). Of the tumors, which regressed after ovariectomy 
40% (15/39) were classified as estradiol-responsive and 60% (24/39) as 
estradiol-unresponsive. 
It has to be emphasized that in the same animal the tumors responded 
differently to endocrine treatment. It occurred that after ovariectomy one 
tumor showed growth accompanied by regression of others. 
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Fig. 3.3 Classification of DMBA—induced rat mammary tumors on the basis of 
growth response to ovariectomy and subsequent estradiol administra­
tion. 
A: ovarian-independent tumor ; B: ovarian-dependent tumor 
C: estradiol-responsive tumor ; D: estradiol-unresponsive tumors. 
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3.3.1 Estradiol and progesterone receptor levels before ovariectomy in 
ovarian-dependent and ovarian-independent Lienors. 
In 20 from the 55 ovarian-dependent and in all 9 ovarian-independent 
tumors ER was measured. PgR was assayed in 16 of these 20 ovarian-dependent 
and in 7 of the 9 ovarian-independent tumors. Representative Scatchard plots 
from 6 points assays are presented in Fig. 3.4. The uncorrected plots were not 
3 3 linear indicating that both H-Ε» and H-R5020 were bound to at least two 
different binding proteins (see also chapter 2.3.1). After correction for 
nonspecific binding linear plots were obtained with low K,-values. The K,-
values obtained were similar in ovarian-dependent and ovarian-independent 
tumors: К for ER 0.32 +_ 0.03 (n=20, dependent) and 0.40 + 0.05 (n=9, inde­
pendent), К for PgR 2.9 + 0.4 (n=16, dependent) and 2.4 + 9 nM (n=5, inde­
pendent). The steroid specificity of ER and PgR binding sites did not differ 
for ovarian-dependent and ovarian-independent tumors. ER was present in all 
tumors, the levels ranged from 15 - 305 in ovarian-dependent and from 10 - 80 
fmoles/mg protein in ovarian-independent tumors (Table 3.1). Although there 
was no sharp distinction between dependent and independent tumors, the ER 
levels of the dependent tumors were significantly higher than those of the 
independent tumors (p<0.01, Wilcoxon rank test). 
Table 3.1 also shows that, in spite of ovarian-independency 5 out of 7 
tumors contained PgR binding sites. The PgR levels ranged from 45 - 385 in 
ovarian-dependent and from 0-185 fmoles/mg protein in the ovarian-inde­
pendent tumors, showing again a considerable overlap. Statistically however 
the PgR levels in ovarian-dependent tumors were significantly higher than in 
ovarian-independent tumors (p<0.05, Wilcoxon rank test). 
The relation between both the ER and PgR levels in the ovarian-dependent 
and ovarian-independent tumors is illustrated in Fig. 3.5. In the dependent 
tumors the correlation coefficient between these levels was significant 
(r = 0.61, p<0.02). No such correlation was found in the independent 
Spearman 
tumors (r =0.05, p>0.1). 
Spearman r 
Analogous to studies of other investigators of hormone-dependency of 
tumors arbitrarily chosen "critical levels" (25 fmoles/mg protein for ER and 
55 fmoles/mg protein for PgR) have been drawn in Fig. 3.5 (DeSombre et al, 
1976; Jensen et al., 1975). All tumors with both receptor levels above these 
"critical levels" belonged to the group of ovarian-dependent tumors. 
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Table 3. 1 Estradiol and progesterone receptor levels before ovariectomy in 
ovarian-dependent and ovarian-independent mammary tumors. 
ER 
(fmoles/mg protein) 
ovarian-
dependent 
tumors 
15 
25 
35 
40 
50 
50 
60 
65 
75 
75 
95 
100 
100 
100 
110 
135 
160 
175 
175 
305 
97 + 15a 
(n=20) 
ovarian-
independent 
tumors 
10 
10 
15 
15 
15 
20 
25 
35 
80 
25 + 7 
(n-9) 
> • 
(fmol 
ovarian-
dependent 
tumors 
45 
45 
60 
75 
75 
80 
85 
110 
125 
130 
185 
205 
230 
275 
285 
385 
PgR 
e s /mg pro tein) 
ovarian-
independent 
tumors 
0 
0 
20 
55 
55 
100 
185 
149 + 25 
(n=16) 
60 + 25 
(n=7) 
Mean + S.E. 
ж*р<о.оі (ovarian-dependent vs. ovarian-independent, Wilcoxon rank test) 
Ά'ρ<0.05 (ovarian-dependent vs. ovarian-independent, Wilcoxon rank test). 
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Fig. 5.5 Relation of pre treatment progesterone and estradiol receptor 
levels of ovarian-dependent (·) and ovarian-independent (O) 
DMBA-induoed rat mammary tumors. Broken lines indicate arbi­
trarily chosen "critical levels". 
On the other hand 3 tumors with ER and PgR l e v e l s below these " c r i t i c a l 
l e v e l s " were ovarian-independent. From the remaining 7 tumors with e i t h e r 
ER or PgR leve l s below one of the " c r i t i c a l l e v e l s " 3 were ovarian-dependent 
and 4 ovarian-independent. 
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3.3. Ρ, Estradiol and progesterone receptor levels before ovariectomy in 
estradiol-responsive and estradiol-unresponsive twr.ors 
It is well known that most but not all tumors that regress after 
ovariectomy regrow after estradiol administration (Nicholson and Colder, 1975; 
Bradley et al., 1976). Often tumors are considered as hormone-responsive or 
hormone-dependent only, when regrowth after estradiol stimulation occurs. This 
to ensure that the regression was due to removal of endogenous hormone and was 
not spontaneous which occurs in these experimental tumors (Young and Cowan, 
1963). 
Table 3.2 Pre-ovariectomy ER and PgR levels in estradiol-responsive and 
estradiol-unresponsive tumors. 
Estradiol-responsive 
ER PgR 
(fmoles/mg protein) 
Estradiol-unresponsive 
ER PgR 
(fmoles/mg protein) 
60 
75 
75 
100 
175 
175 
110 + 21 a 
(n=6) 
85 
75 
205 
285 
230 
125 
165 + 85 
(n-6) 
15 
25 
35 
50 
50 
35 + 7 
(n-5) 
185 
45 
45 
80 
75 
87 + 26 
(n=5) 
Mean + S.E. 
Therefore the group of tumors which regressed after ovariectomy was sub­
divided: tumors were classified as estradiol-responsive when regrowth occurred 
after estradiol treatment and as estradiol-unresponsive when no regrowth was 
observed. 
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Estradiol-responsiveness was assessed in 11 out of the 16 ovarian-depen-
dent tumors in which both ER and PgR levels had been measured (Table 3.1). Six 
of these 11 tumors appeared estradiol-responsive. The pre-ovariectomy ER and 
PgR levels of both estradiol-responsive and estradiol-unresponsive tumors are 
collected in Table 3.2. ER values in the estradiol-responsive tumors were all 
higher than the values observed in the estradiol-unresponsive tumors. The PgR 
levels of both groups of tumors showed a considerable overlap. Tumor regrowth 
occurred with estradiol administration in those tumors that had relatively 
high pre-ovariectomy ER and PgR levels. 
It may be noted that the 3 ovarian-dependant tumors with ER or PgR 
values falling below one of the "critical levels" drawn in Fig. 3.5 belonged 
to the estradiol-unresponsive group. 
3.4. Effect of ovariectomy and of estradiol administration on estradiol and 
progesterone receptor levels 
3.4.1 Effect of ovariectomy on estradiol and progesterone receptor levels 
Although after ovariectomy the estradiol receptor levels of ovarian-de-
pendent tumors on the average, declined to approximately 50% of the pretreat-
ment values (Fig. 3.6), in 9 of the 18 tumors the values did not decrease. In 
6 out of 7 ovarian-independent tumors the receptor levels did not change 
essentially after ovariectomy. The PgR levels of ovarian-dependent and 
ovarian-independent tumors, before and after ovariectomy are shown in 
(Fig. 3.7). Ovariectomy strikingly decreased PgR levels in both dependent 
and independent tumors. It seems worth mentioning that the highest three 
post-ovariectomy values of the ovarian-dependent tumors were obtained in 
biopsies taken on days 3, 4 and 7 after ovariectomy. From both Fig. 3.6 and 
3.7 it follows that after ovariectomy PgR in most tumors became undetectable, 
despite the preservation of ER. 
3.4.2 Effect of estradiol administration on estradiol and progesterone 
receptor levels 
After assessing ovarian dependency of the tumors 5 pg estradiol as the 
benzoate (s.c. daily) was administered for 2 to 4 weeks. 
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Estradiol receptor levels decreased to very low or undetectable levels during 
this long term treatment (Fig. 3.8). This decrease might be explained by the 
relatively high dose of estradiol benzoate administered. This could have 
caused occupation of cytoplasmic receptor sites and/or translocation of 
estradiol receptor complexes to the nucleus. 
It is of interest that ER levels also decreased in the uteri of these 
tumor bearing animals, but never became undetectable. The mean +_ S.E. of the 
uterine ER levels after ovariectomy and after estradiol administration to 
ovariectomized animals was A20 +_ 60 (n=6, range 255 - 620 fmoles/mg protein) 
and 75 +_ 10 (n=9, range 40 - 110 fmoles/mg protein), respectively. 
The PgR levels of ovarian-dependent tumors, which were analysed before 
and after estradiol are shown in Fig. 3.9. In all tumors (n=8), which 
regressed after ovariectomy, estradiol treatment increased PgR levels. It is 
worth mentioning that during estradiol administration all tumors (n=8) 
showed PgR increase, whereas 4 tumors did not regrow. The PgR levels of 
ovarian-dependent tumors before ovariectomy (149 +_ 25, n=16) and of dependent 
tumors of ovariectomized animals receiving estradiol (191 +_ 40 fmoles/mg 
protein, n=8) were not different (p>0.1, Wilcoxon rank test). 
3. 5 Discussion 
All DMBA-tumors analysed in the present investigation contained detec-
table amounts of ER. Therefore it is impossible to distinguish ovarian-depen-
dent from ovarian-independent tumors solely on the presence or absence of ER, 
a possibility, which has been claimed by some authors (McGuire and Julian, 
1971; Nomura et al., 1974), but recently denied by others (Mobbs and Johnson, 
1974; Boylan and Wittliff, 1975; DeSombre et al., 1976). It is of particular 
interest that pre-ovariectomy ER levels of the ovarian-dependent tumors were 
significantly higher than the ER levels of the ovarian-independent tumors. 
Eighteen out of 20 ovarian-dependent tumors had receptor levels >25 fmoles/mg 
protein, whereas 7 out of 9 independent tumors showed levels equal to or below 
this value. 
It may be noted that in the present study biopsies of the tumors were 
taken before ovariectomy, whereas in other investigations, which also 
attempted to relate the level of ER to ovarian-responsiveness of DMBA-tumors, 
ER levels were measured after the respons to ovariectomy was assessed (Boylan 
and Wittliff, 1975; DeSombre et al., 1976). 
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In that case several weeks may have relapsed between ovariectomy and 
excision of the tumor for receptor analysis, a procedure which, as ovariecto-
my may have a pronounced effect on ER levels, might not be preferable. 
It may be stressed that among the ovarian-dependent tumors a small number 
showed low pre-ovariectomy ER values indicating that there is no straight 
forward relation between estrogen binding capacity of a tumor and its growth 
response to ovariectomy as was also observed by other investigators (Mobbs and 
Johnson, 1974; Boylan and Wittliff, 1975; DeSombre et al., 1976). 
Results from this investigation demonstrate that ovarian-independent 
tumors can contain significant amounts of cytoplasmic progesterone receptor. 
The PgR levels in 5 out of 7 independent tumors ranged from 20 - 185 fmoles/ 
mg protein. This finding does not support the attractative hypothesis of 
McGuire et al. (1975) regarding PgR as an ideal marker of hormone dependence. 
McGuire et al. (1975) reasoned, "that the presence of the progesterone re-
ceptor in ER-positive tumors would indicate that the tumor is capable of 
synthesizing at least one end product under estrogen regulation and may there-
fore be endocrine-responsive". Recently these authors emphasized that a 
number of observations (e.g. in a tumor cell line, which growth appeared to 
be estrogen-independent, PgR was estrogen controlled) indicate that effects 
of estrogens on growth and on PgR might well be dissociated (Horwitz and 
McGuire, 1978). As will be discussed later some results of the present study 
are in accordance with this conclusion. 
At the time this investigation was started it was unknown whether PgR 
in DMBA-tumors is under acute control of estradiol as in normal target 
tissues. The results presented in this chapter strongly suggest - in 
accordance with recent reports - that indeed PgR is controlled by estradiol 
in the malignant transformated cells of DMBA-tumors: ovariectomy caused a 
precipitous fall in PgR levels to very low or undetectable levels, whereas 
estradiol administration after ovariectomy induced a pronounced increase in 
PgR levels (Tsai and Katzenellenbogen, 1977; Horwitz and McGuire, 1977; 
Kelly et al., 1977; Pearson et al., 1977; Asselin and Kelly, 1978). It is 
noteworthy that the fall in PgR levels after ovariectomy was not restricted 
to ovarian-dependent tumors but was also observed in ovarian-independent 
tumors. This observations points to the above mentioned dissociation between 
estradiol responsiveness and estradiol induced PgR synthesis. Another obser-
vation is in line with such dissociation: the increase in PgR levels in a 
number of tumors, induced by estradiol administration, did not coincide with 
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regrowth of the tumor. These results suggest that in DMBA-tumor cells PgR 
synthesis remains estradiol controlled even when the growth of the tumor has 
become estrogen-independent. 
Some authors (McGuire and Julian, 1971; Mobbs and Johnson, 1974) consider 
a tumor as being unequivocally hormone-dependent only when regression of the 
tumor occurs upon ovariectomy and a regrowth is observed when estradiol is 
administered subsequently. When these criteria would have been used in the 
present investigation, the unequivocal hormone-dependent tumors all had 
relatively high estradiol and relatively high progesterone receptor levels. 
In the present study it was found that measurement of ER or PgR levels 
were of equal value to predict ovarian-dependency or -independency of DMBA-in-
duced rat mammary tumors. Nevertheless absolute discrimination between both 
groups of tumors could not be reached by either parameter or both. Several 
possibilities can be considered why more adequate predictability of ovarian-
dependency had not been reached. First, as has recently been reported, levels 
of ER, and this certainly may also hold for PgR, fluctuate during the oestrus 
cycle (Hawkins et al., 1977; Shih an'd Lee, 1978), a fact which has not been 
taken into account in the present study. Second, it is possible that other 
hormones are also involved in the growth regulation of DMBA-induced breast 
cancer. A serious candidate in this respect is the peptide hormone prolactin. 
There is a growing body of evidence that prolactin acts in concert with 
estradiol in regulating tumor growth in these experimental tumors (Leung, 
1978). Third, receptor levels in this study are related to the protein content 
of the cytosol, that means that not only tissue protein, but also plasma 
proteins are involved. It might be preferable to express the receptor binding 
capacity on the basis of DNA content. 
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CHAPTER 4 
ESTRADIOL AND PROGESTERONE RECEPTORS IN DMBA-INDUCED MAMMARY TUMORS BEFORE AND 
DURING TAMOXIFEN ADMINISTRATION. 
4.1 Introduction 
Antiestrogens are a class of compounds which prevent estrogens from 
expressing their full effect on estrogen target tissues (Katzenellenbogen and 
Ferguson, 1975; Burnett Lunan and Klopper, 1975). Although the mechanism of 
action of antiestrogens is not clearly defined, it is generally accepted that 
an interaction with the estradiol receptor is an essential step. Antiestro-
gens compete with estradiol for the cytoplasmic estradiol receptor and inhibit 
the uptake of labeled estradiol by estrogen-sensitive target tissues e.g. 
uterus and vagina (Rochefort and Capony, 1972; Terenius and Ljungkvist, 1972). 
Antiestrogens are capable of stimulating the translocation of estradiol 
receptors from the cytoplasm to the nucleus, which results in a prolonged 
depletion of cytoplasmic estradiol receptors (Ruh and Ruh, 1974; Capony and 
Rochefort, 1975; Katzenellenbogen and Ferguson, 1975; Jordan et al., 1977). 
Clarke et al. (1973) have suggested that antiestrogens may produce their 
antagonistic effects by inhibiting the resynthesis of cytoplasmic estradiol 
receptors. 
Antiestrogens are widely used in the palliative treatment of advanced 
breast cancer, mainly in postmenopausal patients (Cole et al., 1971; Ward, 
1973; Heuson, 1976). Furthermore it has been reported that antiestrogens 
inhibit the growth of DMBA-induced rat mammary tumors (Nicholson and Colder, 
1975; Jordan and Koerner, 1975; Jordan, 1976). There is ample evidence that 
also in these tumors the action of antiestrogens is directly mediated by the 
estradiol receptor system (Nicholson et al., 1976; Nicholson et al.", 1977 II; 
Jordan and Koerner, 1975). Two recent studies suggested a relation between 
growth response of DMBA-tumors to the antiestrogen tamoxifen and the estradiol 
receptor levels (Jordan and Jaspan, 1976; Nicholson et al., 1977). No 
information is available with regard to the progesterone receptor. 
In the present study the relation between pretreatment ER as well as PgR 
levels and tumor response to tamoxifen administration was investigated. In 
addition the effect of this treatment on ER and PgR levels was studied. In 
the course of this investigation it appeared that during tamoxifen admini-
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stration tumor growth became autonomous. It seemed of interest to determine the 
presence of ER and PgR in these autonomous tumors and particularly whether the 
synthesis of PgR, if present, was still under estrogen control. 
4.2 Experimental procedures 
4.P.1 Tamoxifen treatment and excision of tumor biopsies 
Induction of DMBA-tumors was described in 3.2.1. In this experiment 
Sprague-Dawly rats of a different strain (IFFA Credo, France) were used, of 
which it was reported that only one to three mammary tumors appear after the 
administration of 20 mg DMBA (Vignon and Rochefort, 1976). Twenty-nine percent 
(22/75) of these animals died within two weeks after DMBA-admimstration. From 
Fig. 3.1 it can be seen that the rate of appearance of mammary tumors was 
similar in both strains of animals. The average number of mammary tumors per 
rat was somewhat lower than in the first experiment, but still reached the 
value of 4.5 (Fig. 3.2). 
Biopsies before tamoxifen administration were taken of tumors that 
reached an area of about A sq. cm (see 3.2.2). When tumors regained prebiopsy 
size the animals received daily s.c. injections of 200 pg tamoxifen in 0.1 ml 
sesame oil. After 3 weeks of tamoxifen treatment a second biopsy was taken 
from the same tumor already biopsied before. Thereafter tamoxifen treatment 
was continued until the animals had multiple rapidly growing tumors About 
two weeks after tamoxifen withdrawal biopsies of these growing tumors were 
taken. 
4.2.2 Classification of rnamravy tumors 
Regression occurred more slowly during tamoxifen administration in this 
study than after ovariectomy, described in the previous chapter. Therefore 
tumors were followed for 3 weeks before tumor response could be assessed. 
Growth patterns of tumor types included in the receptor studies are presented 
in Fig. 4.1. Tumors that had decreased at least 50% in size during 3 weeks 
of tamoxifen administration were scored as regressing tumors (Fig. 4.1a), 
whereas tunors that remained stable or continued to grow were scored as non-
regressmg tumors (Fig. 4.1b). 
In a preliminary experiment the effect of 50 and 200 pg tamoxifen daily 
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Fig, 4.1 Growth patterns of representative DMBA-induaed rat tumors during 
200 \ig tamoxifen treatment. 
A: regressing tumor 
B: non-regressing tumors. 
on tumor growth was studied. Table 4.1 shows that after 3 weeks of 50 yg 
tamoxifen treatment 22% of these DMBA-tumors appeared to be regressing, 
whereas after 3 weeks of 200 ug tamoxifen 70% of the tumors were scored as 
regressing (p<0.001). In the receptor studies only tumors of animals, are 
included, which received 200 ug tamoxifen daily. 
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Table 4.1 Машпагу tumor growth response to three weeks of tamoxifen treatment. 
Treatment 
50 yg tamoxifen/day 12 
200 \ig tamoxif en/day 12 
[O of 
ats 
no of 
tumors 
50 
47 
Regressing 
tumors 
11 (22%)* 
33 (70%) 
Non-regressing 
tumors 
39 (78%) 
14 (30%) 
The tumor responses have been assessed after 3 weeks of tamoxifen treatment. 
Tumors regressing to 50% of their pretreatment size were scored as regressing 
tumors. 
The remaining tumors that remained static or grew despite this treatment were 
scored as non-regressing tumors. 
* χ
2
 = 20.8; DF = 1; p<0.001 (50 yg vs 200 yg tamoxifen). 
Table 4.2 Estradiol and progesterone receptor levels in simultaneously 
taken biopsies from different tumors of the same animal. 
Animal ER PgR 
(fmoles/mg protein) 
tumor 
classification 
1 
2 
3 
4 
tumor 
tumor 
tumor 
tumor 
tumor 
tumor 
tumor 
tumor 
A 
В 
A 
В 
A 
В 
A 
В 
50 
75 
20 
95 
75 
35 
35 
60 
670 regressing tumor 
670 regressing tumor 
80 regressing tumor 
130 regressing tumor 
170 regressing tumor 
0 non-regressing tumor 
45 non-regressing tumor 
145 non-regressing tumor 
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4.¿ Estradiol and progesterone receptor levels before tamoxifen treatment in 
regressing and non-regressing tiwors 
ER and PgR were measured in 24 tumor biopsies (19 animals) taken before 
200 )jg tamoxifen treatment. Of 4 animals two biopsies have been simultaneously 
taken from different tumors of the same animal (Table 4.2). It appeared that 
ER and PgR levels showed a wide range even in these tumor biopsies, that were 
simultaneously taken at the same stage during the oestrus cycle. Interesting-
ly in animal no. 3 one of the tumors was scored as regressing and the other as 
non-regressing. 
Table 4.3 shows the individual ER and PgR levels of regressing and non-
regressing tumors. Detectable amounts of ER were found in 21 out of 24 tumors 
studied. The ER levels ranged from 0-95 in the group of the regressing tumors 
and from 0-60 fmoles/mg protein in the group of non-regressing tumors, thus 
showing a considerable overlap. Nevertheless the ER levels of the regressing 
tumors were significantly (p<0.05, Wilcoxon rank test) higher than those of 
the non-regressing tumors. 
All regressing tumors (n=15) and 5 out of 9 non-regressing tumors re-
vealed the presence of PgR. Although there was overlap of the lower values of 
the regressing tumors (range 40-900 fmoles/mg protein) and the higher values 
of the non-regressing tumors (range 0-255 fmoles/mg protein), regressing 
tumors had significantly higher PgR levels than non-regressing tumors (p<0.01, 
Wilcoxon rank test). 
The relation between ER and PgR levels of regressing and non-regressing 
tumors is shown in Fig. A.2. Remarkably in this experiment a significant 
correlation between individual ER and PgR levels in both groups of tumors was 
not observed (regressing tumors: r„ = 0.37, p>0.I and non-regressing 
ь ь
 Spearman 
tumors: r„ =0.11, p>0.1). Using arbitrarily chosen "critical levels" 
Spearman r 0 J 
of 20 fmoles/mg protein for the estradiol receptor and of 150 fmoles/mg 
protein for the progesterone receptor, it appeared that all tumors (11/11) 
with both receptor levels above these "critical levels" regressed during 
3 weeks of 200 yg tamoxifen administration. On the other hand only 4 out of 
the 13 remaining tumors with either an ER value below and/or a PgR value below 
2 
these "critical levels" regressed during this treatment (χ = 9.41; DF = 1; 
p<0.01). Three tumors contained ER (15-35 fmoles/mg protein) whereas no PgR 
was detectable and all 3 tumors failed to regress during tamoxifen. Interes­
tingly in 2 tumors PgR activity was present whereas no ER was detectable. 
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Table 4.3 Estradiol and progesterone receptor levels before tamoxifen treat-
ment in regressing and non-regressing tumors. 
ER 
(fmoles/mg 
regressing 
tumors 
0 
20 
25 
30 
35 
35 
40 
45 
50 
50 
50 
60 
75 
75 
95 
46 + 6a 
(n=15) 
protein) 
non-
25 
(n 
regressing 
tumors 
0 
0 
15 
15 
25 
35 
35 
35 
60 
È * 1 6 
= 9) 
PgR 
(fmoles/mg 
regressing 
tumors 
40 
40 
80 
130 
165 
170 
210 
260 
295 
400 
515 
670 
670 
750 
900 
352 + 72 
(n=15) 
p: rotein) 
non-regressing 
tumors 
0 
0 
0 
0 
45 
110 
115 
140 
255 
74 + 30* * 
(n-9) 
Mean + S.E. 
'^p<0.05 (regressing vs. non-regressing, Wilcoxon rank test) 
A#p<o. 01 (regressing vs. non-regressing, Wilcoxon rank test) 
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Fig. 4.2 Relation of pre treatment progesterone and estradiol receptor 
levels of regressing (·} and non-regressing (O) DMBA-induoed 
rat mammary tumors. 
Broken lines indicate arbitrarily chosen "critical levels". 
4.4 Estradiol and progesterone receptor levels before and during tamoxifen 
administration 
Biopsies of the same tumor were taken before and during tamoxifen admi­
nistration. The animals received 200 pg tamoxifen for approximately 3 weeks 
and the tumors were assayed 48 hrs after the last injection. Fig. 4.3 com­
pares ER and PgR levels of the same tumor before and during tamoxifen treat­
ment. During tamoxifen treatment estradiol receptors were undetectable in 
10 tumors and the other 2 showed very low ER levels. Tamoxifen treatment 
markedly reduced PgR levels, but specific progesterone receptor binding re­
mained detectable in 9 out of 12 tumors examined. The mean PgR level before 
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Fig. 4.5 Effect of 200 \ig tamoxifen treatment on estradiol and progesterone 
receptor levels of regressing (·) and non-regressing (O) DMBA-
induced rat mammary tumors. 
treatment was 248 + 55 and declined to 47 + 17 fmoles/mg protein (80% reduc­
tion) after 3 weeks of 200 pg tamoxifen/day. Attention is drawn to the fact 
that ER and PgR levels declined in regressing as well as in non-regressing 
tumors. 
4.b Estradiol and progesterone receptors after tamoxifen withdrawal in 
autonomous tumors 
Within 3-4 months after tamoxifen administration was started new tumors 
developed in every animal. Furthermore about 25% of the tumors that had 
regressed as a result of tamoxifen administration exhibited spontaneous tumor 
regrowth. After tamoxifen withdrawal these growing tumors did not respond to 
ovariectomy. Apparently tumor growth had become autonomous during tamoxifen. 
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Fig. 4.4 Effect of ovarieotomy and of one subsequent estradiol administration 
on progesterone receptor levels of autonomous DMBA-induoed rat 
mammary tumors. Tumors that grew during 200 vg tamoxifen treatment 
and after tamoxifen withdrawal did not respond to ovarieotomy were 
designated as autonomous. 
Biopsies of these autonomous tumors have been taken on day 14 +_ 0.7 
(mean +_ S.E., range 10-21 days) after tamoxifen withdrawal. In 12 out of 19 
tumors analysed detectable amounts of PgR were present. The levels ranged 
from 0 to 170 fmoles/mg protein (39 + 11, mean + S.E.). Despite the fact that 
some tumors contained considerable PgR levels, ER levels were very low 
(<15 fmoles/mg protein) or undetectable (13/19) in all tumors (n=19) after 
tamoxifen withdrawal. 
In these autonomous tumors it was investigated whether the synthesis of 
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Ovariectomy 1x5 jug estradiol 
PgR, as in normal target tissues and in ovarian-dependent DMBA-tumors, is 
under estrogen control. Therefore the effect of ovariectomy and of subsequent 
estradiol administration on PgR levels was studied. About 3 weeks after 
tamoxifen withdrawal the animals were bilaterally ovariectomized. As 
mentioned before these growing tumors did not respond to ovariectomy and were 
therefore designated as autonomous. Biopsies of these autonomous tumors were 
taken 11-22 days after ovariectomy. At the same day the animals received one 
injection of 5 ug estradiol as the benzoate (s.c.). Forty hours after this 
injection the animals were sacrificed and the tumors were excised for recep-
tor analysis. The PgR levels of autonomous tumors measured before and after 
ovariectomy and after subsequent estradiol administration are collected in 
Fig. 4.4. It can be seen that ovariectomy decreased PgR levels in those 3 
tumors, that contained detectable amounts of PgR before ovariectomy. A single 
injection of 5 yg estradiol as the benzoate increased the concentration of 
PgR binding sites in 6 out of 9 tumors studied. The remaining 3 tumors were 
PgR-negative before and after estradiol administration. 
4.6 Dbsoussion 
Antiestrogens may elicit tumor regression of established DMBA-induced 
rat mammary tumors. In the present study 20% of the tumors regressed during 
daily administration of 50 yg of tamoxifen. In good agreement with several 
other reports 200 yg of tamoxifen caused tumor regression of 70% of the 
tumors (Jordan and Koerner, 1976; Nicholson and Colder, 1975). The regression 
of tumors to tamoxifen administration appeared to be related with the quanti-
tative estradiol receptor binding capacity. Tumors, that regressed during the 
administration of 200 yg tamoxifen had significantly higher ER levels than 
non-regressing tumors. However there was no absolute division between both 
groups of tumors on the basis of ER levels, because the lower levels of 
regressing tumors and the higher levels of non-regressing tumors showed a 
considerable overlap. These observations are in accordance with recent 
reports of Jordan and Jaspan (1976) and Nicholson et al. (1977), who both 
observed that tumors which remained static or continued to grow during 
tamoxifen administration had very low ER values, whereas regressing tumors 
had higher ER values. 
As appears from the results reported here, progesterone receptors were 
detectable in all regressing and in 5 out of 9 non-regressing tumors. 
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This indicates that there is no absolute relation between the presence or 
absence of PgR and the endocrine responsiveness of these tumors. Interestingly 
total absence of detectable PgR occurred only in tumors that failed to regress 
during tamoxifen. A tighter relation of tumor response to tamoxifen admini-
stration was obtained when both receptor levels were taken into account. This 
observation indicates that measurement of PgR along with ER provides 
additional although not definitive information with regard to responsiveness 
of DMBA-induced mammary tumors to tamoxifen treatment. 
After the administration of 200 v<g tamoxifen/day for a period of 3 weeks 
ER levels in the cytoplasmic fraction became very low or undetectable. Recent-
ly Tsai and Katzenellenbogen (1977) reported that in DMBA-tumor cells during 
treatment with the antiestrogen U-23, 469 (Upjohn Company) over 90% of ER was 
localised in the nucleus with concomitant low levels of ER in the cytoplasmic 
fraction. These investigators suggested that this situation may render the 
tumor cells insensitive to the animal's own endogenous estrogen and, hence, 
unable to grow. 
During tamoxifen administration PgR levels markedly decreased in both 
the regressing and non-regressing tumors. During this endocrine intervention 
the effects on tumor growth and on PgR synthesis appearently were not related. 
Tsai and Katzenellenbogen (1977) recently analysed the effect of a new anti-
estrogen on PgR activity in DMBA-tumors, that regressed during this treatment. 
In contrast to our observation these investigators observed only a slight 
decrease in PgR levels, a difference that may be caused by divergent pathways 
in the mechanism of action of the antiestrogens used. Interestingly these 
investigators also emphasized dissociation between effects on growth and on 
PgR synthesis. 
From our study it appeared that during long term tamoxifen treatment new 
growing tumors developed, whereas regressed tumors showed a spontaneous re-
growth. After tamoxifen withdrawal these growing tumors did not respond to 
ovariectomy, suggesting that tumor growth had become autonomous. ER levels 
were very low or undetectable in these autonomous tumors after tamoxifen 
withdrawal. It is unknown, whether these very low ER levels are due to the 
previous tamoxifen treatment, resulting in a prolonged depletion of estradiol 
receptors in the cytoplasm, or are related to the fact that these tumors are 
autonomous. In most of these autonomous tumors PgR not only was detectable, 
but was still inducible by estradiol as is indicated by the decreased PgR 
levels after ovariectomy and the increased PgR levels after E treatment. 
2 
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CHAPTER 5 
ESTRADIOL AND PROGESTERONE RECEPTORS IN PRIMARY AND METASTATIC HUMAN BREAST 
CANCER. 
6.1 Introduction 
In normal target tissues the concentrations of estradiol and progesterone 
receptors are regulated by steroid hormones (Bayard et al., 1978). There is 
ample evidence that also in DMBA-induced rat mammary tumors steroid hormones 
exert acute control over the production of ER and PgR. In DMBA-tumors 
estradiol receptors are stimulated by estradiol and prolactin, whereas pro-
gesterone inhibits ER synthesis (Sasaki and Leung, 1975; Leung and Sasaki, 
1975; Kelly et al., 1978). On the other hand PgR synthesis in these tumors 
is induced by estradiol (see chapter 3). 
The observation that tumors from premenopausal patients have lower ER levels 
than tumors from postmenopausal patients suggests that receptor levels in 
human breast tumors may be modulated by circulating steroid hormones 
(McGuire, Carbone and Vollmer, 1975). 
In this chapter the distributions of ER and PgR in primary and meta-
static human breast cancers are presented. The data were evaluated with 
special emphasis on the menopausal status and the use of contraceptive 
steroids. To our knowledge no studies have been reported regarding the 
influence of contraceptive steroids on ER and PgR levels in human breast 
cancer. 
Recently it has been questioned whether receptor assays performed in 
the primary tumor at time of mastectomy can be used to guide endocrine 
therapy at time of recurrence (Jensen et al., 1975). In other words, is 
there a relation between receptor activity in the primary tumor and in 
metastatic lesions at time of recurrence? This would be of clinical im-
portance because many patients have metastatic lesions, that are in-
accessible for excision. To investigate this attractive possibility se-
quential receptor assays were performed in the primary breast tumor and 
metastases of the same patient. Furthermore multiple sequential biopsies of 
metastases of the same patient were analysed for the presence of ER and 
PgR in order to study the evolution of receptor activity during the course 
of this disease (Singhakowinta et al., 1976, Kiang et al., 1977). 
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There is only very limited information available in the literature about 
the effect of endocrine therapy on ER and PgR levels of human breast tumors 
(Walt et al., 1976). Moreover there is no conclusive information as to how 
much time is required before biopsies can be analysed for receptor activity 
after discontinuation of estrogen (ethynylestradiol) or antiestrogen (tamoxi­
fen) treatment. Therefore sequential biopsies of metastases of the same 
patient have been analysed for receptor activity before, during and after 
tamoxifen or ethynylestradiol treatment. In addition tumors have been studied 
before and after ovariectomy. 
5.2 Estradiol and Progesterone receptors in Primary and Metastatic Breast 
tumors 
Biopsies of 297 primary and 91 metastatic breast tumors have been 
analysed for the presence of estradiol receptors (ER) and progesterone re­
ceptors (PgR). The incidence of both receptors in primary and metastatic 
breast tumors is presented in Table 5.1. Biopsies of metastases obtained 
within six weeks after tamoxifen withdrawal were excluded. 
Table 5.1 Incidence of ER and PgR in human breast cancer. 
Total Primary Metastatic 
ER-positive 71% (277/388) 74% (219/297)a 64% (58/9l)a 
PgR-positive 51% (199/388) 55% (165/297)b 37% (34/91)b 
a
 χ
2
= 3.41 ; DF = 1 ; 0.1>p>0.05 
b
 χ
2
= 9.23 ; DF = 1 ; p<0.01 
Of all tumors (n=388) analysed 71% were ER-positive and in 51% of the tumors 
PgR could be detected. The frequency of PgR-positive tumors was significantly 
higher (p<0.01) in primary (55%) than in metastatic tumors (37%). Primary 
breast tumors were also more likely to be ER-positive than metastases, the 
difference being close to statistical significance (0.1>p>0.05). The dis­
tribution of PgR-positive tumors, in relation to the presence or absence 
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of ER, can be seen in Table 5.2. 
Table 5.2 Distribution of PgR-positive human breast tumors. 
Total Primary Metastatic 
ER+ PgR+ 68% (189/277) 72% (157/219)a 55% (32/58)a 
ER- PgR+ 9% (10/111) 10% (8/78) 6% (2/33) 
a
x
2
= 5.77 ; DF = 1 ; p<0.02 
Tt appeared that the presence of PgR was essentially restricted to ER-
positive tumors. In the group of ER-positive tumors 68% were also PgR-posi­
tive whereas only 9% of the ER-negative tumors were PgR-positive. The 
frequency of ER+ PgR+ tumors was significantly (p<0.02) higher in primary 
(72%) as compared to metastatic breast tumors (55%). In these series of 
patients, 10 (2.6%) showed PgR, whereas no ER could be detected. Most 
(7/10) of these tumors had very low PgR levels (<20 fmoles/mg protein). 
Six out of these 10 patients appeared to be premenopausal. 
•5.3 Estradiol and Progesterone Receptors in Primary Breast Tumors 
5.3.1 Influenae of Menopausal status on steroid hormone receptors 
The influence of the menopausal status on the receptor distributions 
and the receptor levels was examined. A woman was considered as postmeno­
pausal when menses had ceased at least one year prior to biopsy. The 
receptor distributions of these groups of patients is presented in Table 5.3. 
2 
It appeared that postmenopausal patients were more likely (χ =3.57 ; 
0.1>ρ>0.05) to have ER-positive tumors (78%) than premenopausal women 
(67%). The frequency of PgR-positive tumors however was not different 
for these two groups of women. 
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Table 5.3 ER and PgR distributions in primary breast tumors of pre- and 
postmenopausal patients. 
number of patients ER+ ER+ ER- ER-
analysed PgR+ PgR- PgR+ PgR-
premenopausal 76 57% 10%a 7% 26% 
postmenopausal 167 53% 25%a 2% 20% 
a
x
2
= 6.83 ; DF = 1 ; p<0.01 
The difference in ER distribution between pre- and postmenopausal patients 
was due to ER+ PgR- tumors being significantly (p<0.01) more frequent in 
postmenopausal patients (25%) as compared to premenopausal patients (10%). 
The mean receptor levels of the receptor-positive tumors of these two 
groups of women are collected in Table 5.4. 
Table 5.4 ER and PgR levels in primary breast tumors of pre- and postmeno­
pausal women (ER- PgR- tumors excluded). 
Patients 
premenopausal 
postmenopausal 
Estradiol Rei 
mean + S.E. 
62 + 7 (51)b 
202 + 19*( 131) 
ceptor 
a 
range 
9-220 
20-1400 
Progesterone Re 
mean + S.E. 
193 + 29 (48)C 
190 + 28 (92) 
ceptor 
a 
range 
8-1250 
8-1230 
all values are expressed as fmoles/mg protein 
the number of estradiol receptor-positive tumors is indicated in paren­
theses 
с 
the number of progesterone receptor-positive tumors is indicated in 
parentheses 
'*p<0.01 (pre-vs. postmenopausal women, Wilcoxon rank test). 
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The mean receptor level of the estradiol receptor-positive tumors of pre­
menopausal patients was significantly lower than the corresponding mean 
receptor level of postmenopausal patients. No such difference was observed 
for the mean level of PgR. 
5.3.2 Influenae of Age on Steroid hormone receptors 
In Figs. 5.1 and 5.2 the ER and PgR levels of primary breast tumors are 
plotted against the age of the patient. 
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Fig. b.l ER levels in primary breast tumors plotted against the age of 
the patient. 
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Fig. 5.2 PgR levels in primary breast tumors plotted against the age of 
the patient. 
It is noteworthy that frequently ER levels of patients older than 50 years 
of age (predominantly postmenopausal) were higher than the upper level 
obtained in younger patients (predominantly premenopausal). No such 
difference was observed for PgR values. As Table 5.5 shows the frequency of 
ER-positive tumors increased with age. The difference between the percen­
tage of ER-positive tumors in the group of women younger than 40 and older 
2 
than 60 was close to statistical significance (χ = 3.51 ; DF = 1 ; 0.1>p> 
0.05). There appeared to be no consistent influence of the age of the 
patient on the incidence of PgR-positive primary breast tumors. 
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Table 5.5 ER and PgR distribution in primary breast tumors: Influence of 
age. 
age number of patients ER-positive PgR-positive 
(years) analysed (%) (%) 
<40 23 61 52 
40-50 59 69 66 
50-59 77 71 49 
>60 115 79 57 
5.3.3 Influenae of contraceptive steroids an steroid hormone receptors 
Some of the premenopausal patients used contraceptive steroids (Lyndiol 
R R R R 
Stediril d , Neogynon , Microgynon and Orthonovum ) just prior to tumor 
biopsy excision. Receptor distributions and levels were compared in two 
groups of premenopausal women; contraceptive steroid users and non-users. 
The ER levels of the non-users ranged from 0 to 120 fmoles/mg protein. 
Interestingly 6 out of 23 users with ER-positive tumors showed values above 
this level (120-220 fmoles/mg protein). The range of PgR levels was similar 
for both types of patients (0 to about 1000 fmoles/mg protein). No 
statistically significant differences in the frequency of ER-positive and 
PgR-positive tumors between these two groups of patients were observed 
(Table 5.6). 
5.Z.4 Correlation between estradiol and progesterone inceptor binding sites 
in primary breast tumors 
Estradiol receptor levels have been plotted against the corresponding 
progesterone receptor levels separately for pre- (Fig. 5.3) and postmeno-
pausal patients (Fig. 5.4). No correlation was observed between the levels 
of ER-positive and PgR-positive tumors in either category of patients. 
R 
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Table 5.6 ER and PgR distribution in primary breast tumors of premenopausal 
women in relation to use of contraceptive steroids. 
ER-positive PgR-positive 
a b 
patients using contraceptive steroids 74% (23/31) 72% (13/18) 
patients not using contraceptive steroids 61% (34/56) 61% (34/56) 
a
x
2
= 1.06 ; DF = 1 ; p>0.1 
bX 2= 0.36 ; DF = 1 ; p>0.5 
When both receptors were present, premenopausal women generally (74%) had 
a PgR/ER ratio above I, whereas 61% of the postmenopausal women had a ratio 
2 
below 1 (χ = 13.74 ; DF = I ; p<0.001). Although no correlation between the 
quantitative ER and PgR values was observed, there was a positive relation 
between the incidence of PgR-positive tumors and the concentration of 
estradiol receptor binding sites (Table 5.7). 
Table 5.7 Comparison of estradiol receptor binding sites and the incidence 
of PgR-positive primary breast tumors. 
ER number of patients PgR-positive 
(fmoles/mg protein) analysed 
0 78 10% 
<30 41 54% 
31-50 29 66% 
51-99 51 73% 
>100 98 82% 
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Fig. 5.3 
Correlation between 
estradiol and pro­
gesterone receptor 
levels in primary 
breast tumors from 
premenopausal patients 
(n=76). Twenty breast 
tumors were regarded 
as ER- PgR-, 
Fig. 5.4 
Correlation between 
estradiol and pro­
gesterone receptor 
levels in primary 
breast tumors from 
postmenopausal patients 
(п=1в7). Thirty-three 
breast tumors were 
regarded as ER- PgR-. 
Estradiol receptor (tmoles / mg protein) 
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5.4 Estradiol and progesterone receptors in normal tissues and in benign 
mammary tumors 
Several biopsy specimens have been analysed for the presence of estradiol 
and progesterone receptors, which on histological examination appeared to be 
nonmalignant (normal breast tissue, skin biopsies and lymph nodes). None of 
these specimens had measurable ER (n=22) or PgR (n=13). Thirteen benign 
mammary tumors, mainly fibroadenomas, have been studies for the presence 
of ER and all were classified as ER-negative. Optili now progesterone re-
ceptors have been analysed in only 3 benign mammary tumors and all 3 specimen 
appeared to be PgR-negative. 
5.5 Estradiol and Progesterone Receptors in different tumor specimens of the 
same patient 
5.5.1 Estradiol and progesterone receptors in two simultaneously excised 
biopsies 
From 8 patients tumor biopsies were simultaneously excised from different 
tumor sites (Table 5.8). The tumors from 7 patients were classified identical, 
either both as ER-positive (n=3) or both as ER-negative (n=4). From 1 
patient two osteolytic bone metastases have been analysed. One specimen 
revealed an ER value of 50 fmoles/mg protein, whereas in the other no ER 
could be detected. It is noteworthy that the histologic examination demon-
strated that the tumor cellularity of these lesions was low. The tumor 
biopsies of 3 patients have also been analysed for the presence of PgR. 
In these 3 patients the classification of both metastases either as PgR-
positive (n=l; PgR: 8 and 30 fmoles/mg protein, patient 3) or as PgR-
negative (n=2, Patients 4 and 8) was the same. 
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Table 5.8 ER in multiple simultaneously taken tumor biopsies from the same 
patient. 
patient Anatomic ER Anatomic ER 
sites (fmoles/mg protein) site (fmoles/mg protein) 
1 
2 
3 
4 
5 
6 
7 
8 
lymph node 
breast 
breast 
breast 
lymph node 
skin 
ovary 
bone 
240 
50 
10 
0 
0 
0 
0 
50 
lymph node 
breast 
breast 
breast 
lymph node 
skin 
ovary 
bone 
70 
20 
15 
0 
0 
0 
0 
0 
S.S.P, Estradiol Reeeptore in tuo sequential biopsies of the primary breast 
tumor from the same patient 
From 4 patients two sequential primary breast tumor biopsies have been 
analysed for the presence of ER. Two patients had an inoperable primary 
tumor and the other two showed recurrence of the primary breast tumor. Two 
patients had on both occasions ER-positive tumors and two patients had 
ER-negative tumors. The ER values of these two patients were 30 and 115, 
and 30 and 25 fmoles/mg protein respectively. 
b.b.6 Sequential Estradiol Receptor assays in the ртітагу breast timor and 
metastases of the same patient 
During the course of this investigation there was opportunity with 
17 patients to obtain a tumor specimen from the primary tumor and at 
various time intervals also from a metastatic lesion. The ER values of 
these patients are collected in Fig. 5.5. It appeared that ER-positive 
primary tumors generally give rise to ER-positive metastases (5 out of 6 
patients), whereas ER-negative primary tumors generally give rise to ER-
negative metastases (10 out of 11 patients). 
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Fig. 5.5 
Comparison of ER levels in 
sequential biopsies of the 
primary breast tumor (») and 
metastases (O) of the same 
patient (n=17). 
Only in 2 out of these 17 patients (12.0%) the receptor classification of 
the primary tumor and of the metastasis at time of recurrence was not in 
agreement. One patient had an ER value of 35 fmoles/mg protein in the 
primary breast tumor, 29 months later a lymph node metastasis appeared 
to be ER-negative, however with a PgR value of 55. This patient was still 
menstruating and the biopsy specimen was excised during the follicular 
phase of the cycle. The other patient had an ER- PgR- primary tumor. Six 
months later a metastasis revealed an ER value of 35 and a PgR value of 
110 fmoles/mg protein. Five out of 6 patients with ER-positive primary 
tumors showed lower ER values in the later appearing metastases. 
5.5.4 Multiple sequential receptor assays in metastases of the same 
patient 
Several patients were followed for extensive periods and with 23 
patients there was opportunity to obtain different metastatic biopsy 
specimens during the course of their disease. Most patients received some 
form of treatment (radio-, chemo- or endocrine therapy) in the interval 
between the tumor excisions. The ER values of these patients are collected 
in Fig. 5.6. 
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b'ig. 5.6 Sequential estradiol receptor assays in metastases of the same 
patient (n=23). 
О first biopsy ; Τ second biopsy 
Metastases of the same patients excised at different times during the course 
of their disease generally were both ER-positive (15 out of 17 patients = 
88%) or both ER-negative (5 out of 6 patients = 83%). Two patients showed 
ER-positive skin metastases and revealed ER-negative metastatic tumors 
3 weeks after termination of ethynylestradiol administration and 6 weeks 
after tamoxifen withdrawal respectively. One patient had an ER-negative 
skin nodule and subsequently received 5-fluoro uracil. Ten months later 
another skin nodule revealed an ER value of 70 fmoles/mg protein. From 13 
patients the ER value of the second biopsy was lower and from 5 patients 
higher compared to the ER value of the formerly excised biopsy specimens. 
In 4 patients, which on two former occasions had ER positive metastatic 
lesions, a third metastasis was available for study. 
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Three of these patients again revealed ER-positive tumors, whereas in the 
fourth patient no ER could be detected. 
From 8 patients different tumor biopsies have also been studied for the 
presence of PgR. The results are collected in Table 5.9. Although the number 
of observations is small, it appeared that in 4 out of 5 cases progesterone 
receptor became undetectable during the course of their disease. 
Table 5.9 Comparison of PgR values in metastatic tumor biopsies from the 
same patient excised at different times. 
Patient first second third 
metastasis metastasis metastasis 
720 
580 
25 
20 
15 
0 
0 
0 
0 
0 
30 
0 
20 
0 
0 
0 
The data are expressed as fmoles/mg protein. 
5.6 Steroid hormone receptor levels before, during and after endocrine 
treatment in biopsies of the same patient 
5.6.1 Estradiol receptor levels before, during and after tamoxifen admini-
stration 
The ER levels measured before, during and after tamoxifen administration 
in sequential biopsies of the same patients are collected in Fig. 5.7. The 
ER levels before treatment ranged between 20 and 480 fmoles/mg protein. 
During tamoxifen administration no cytoplasmic ER binding could be detected 
(n=8). 
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Fig. b.7 ER levels before, during and after tamoxifen (40 mg daily) admini-
stration in sequential biopsies of the same patients. 
In 3 out of 5 patients ER binding increased from 0 during tamoxifen treatment 
to values, that ranged between 30 and 145 fmoles/mg protein after drug with-
drawal. In 8 patients ER was measured before as well as after tamoxifen 
treatment. After tamoxifen withdrawal the ER values appeared to be consi-
derably lower compared to the corresponding values measured before this treat-
ment was started. Two patients with ER-positive metastases before therapy 
revealed ER-negative tumors 6 and 8 weeks after termination of this therapy. 
The interval between drug withdrawal and tumor excision varied between 2 
weeks and 3 months in the other 6 patients with ER-positive tumors after 
tamoxifen treatment. 
¿.6.2 Estradiol and progesterone receptor levels before, during and after 
ethynylestradiol administration 
The results of these observations are summarized in Table 5.10. No 
cytoplasmic estradiol receptor binding could be detected in biopsies of 3 
patients during ethynylestradiol administration (3000 pg/daily). 
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During this treatment progesterone receptors however, in contrast to est-
radiol receptors, were clearly present in all 3 patients studied. After drug 
withdrawal 6 out of 7 patients again had ER-positive metastases. In one 
patient ER binding sites could not be detected in two metastatic lesions 
excised 3 weeks and it months after cessation of this treatment. In the other 
patients with ER-positive tumors, biopsies were obtained A weeks or later 
after ethynylestradiol withdrawal. In Table 5.10 it can be seen that after 
ethynylestradiol withdrawal the ER values of 3 patients were lower and of 
3 patients were higher compared to the corresponding values measured before 
therapy. 
Table 5.10 Steroid hormone receptor levels before, during and after ethynyl-
estradiol administration. 
before during 
ER ER PgR 
210a 0 
60 0 100 
45 0 720 
460 
before after Interval 
ER ER 
820 240 5 weeks 
210 140 2 years 
65 100 4 weeks 
45 0 3 weeks 
35 410 8 weeks 
30 120 4 weeks 
25 30 2 years 
All values are expressed as fmoles/mg protein 
Time interval between ethynylestradiol withdrawal and second biopsy. 
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S.6.3 Estradiol and progesterone receptor levels before and after ovariectomy 
From 5 patients specimens have been analysed before as well as after 
ovariectomy (Table 5.11). All patients showed ER-positive tumors before as 
well as after ovariectomy. However it may be noted that the quantitative ER 
levels in 4 out of 5 patients were lower after ovariectomy. In 1 ovariecto-
mized woman an ER value of 275 fmoles/mg protein was obtained. This value 
was higher than the highest value observed in the group of premenopausal 
patients studied (Table 5.4). From several other patients ER values have 
only been measured after ovariectomy. Also in this group of patients 
occasionally very high ER values were observed up to 490 fmoles/mg protein. 
Therefore it seems that at least in some patients ER values increase when 
they change of menopausal status, because of the removal of their ovaries. 
In one out of three patients the PgR assay was negative 3 weeks after the 
performed ovariectomy. 
Table 5.11 ER and PgR levels before and after ovariectomy. 
before After Interval 
ER 
90a 
70 
60 
75 
60 
PgR 
15 
580 
25 
-
-
ER 
40 
50 
275 
25 
30 
PgR 
20 
0 
30 
-
-
8 weeks 
3 weeks 
21 months 
16 months 
36 months 
All receptor values are expressed as fmoles/mg protein 
Time interval between ovariectomy and second biopsy. 
95 
S.7 Dísoussion 
After the suggestion of McGuire et al. (1975) that PgR could be a sen-
sitive marker for prediction of response to endocrine therapy, various labo-
ratories have developed an assay for the measurement of PgR in biopsies of 
human breast tumors. Today at least 15 laboratories have published data re-
garding ER and PgR in human breast tumors . In these studies the percentage 
of receptor-positive tumors varied between 53 and 86% for ER and between 
27 and 57% for PgR. In only 4 out of these 15 studies information was 
given about the origin of the tumor tissue, whether the biopsy was taken 
from the primary tumor or from a metastatic lesion, and about the menopausal 
status. In the present study 71% of all tumors analysed were ER-positive and 
in 51% of the tumors PgR could be detected. This wide variation of recep-
tor-positive tumors may be due to: 
1. collection and storage conditions especially regarding the thermolability 
of PgR binding sites (chapter 2). 
2. the procedures used for the determination of receptor activity e.g. 
buffer composition, the type of radioactive ligand used and the method 
used for separation of free and bound steroid. 
3. the criteria used for classification tumors either as receptor-positive 
or as receptor-negative e.g. several investigators have arbitrarily de-
fined cut off levels of 20-25 fmoles/mg protein for PgR and every tumor 
showing a lower value is classified as receptor-negative. 
A. a different incidence of receptor-positive breast tumors in patients 
living in different parts of the world e.g. Matsumoto and Sugano (1978) 
reported that tumors from American patients more frequently contained 
ER than tumors from Japanese patients. 
Despite this wide variation in the frequency of PgR-positive tumors all 
investigators agreed that the presence of PgR was essentially restricted 
to ER-positive tumors. In these studies 2-12% of all tumors analysed con-
tained PgR without ER. In this laboratory the frequency was 2.6%. 
(Saez et al., 1978; Matsumoto and Sugano, 1978; Young et al., 1978; Rao 
and Meyer, 1977; May-Levin et al., 1977; Daehnfeldt et al., 1977; Tobin 
et al., 1977; Pichón and Milgrom, 1977; Leclercq et al., 1977; Horwitz 
and McGuire, 1977; DeSombre and Jensen, 1977; Wittliff et al., 1978; 
Daxenbichler et al., 1977; Caffier and Brandau, 1978; Barnes et al., 1977). 
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Interestingly several investigators (Pichón and Milgrom, 1977; Saez et al., 
1978; Horwitz and McGuire, 1977), as in the present study (Table 5.7), ob-
served that the incidence of PgR-positive tumors was positively related 
with increasing ER levels. Tumors with high ER levels were more likely to be 
PgR-positive than tumors with low ER levels. This finding suggests that in 
human breast cancer the progesterone receptor is under estrogen control. 
In most studies primary breast tumors were slightly more often ER-
positive than metastatic tumors, although the difference, as in the present 
study, was not always significant (Beex, 1979; McGuire, Carbone and Vollmer, 
1975; Table 5.1). Several investigators have performed sequential ER assays 
in the primary breast tumor and metastases from the same patient. From 
these reports (Jensen et al., 1975; Rosen et al., 1977; Matsumoto and 
Sugano, 1978; Maass et al., 1975), as from the present study (Fig. 5.5), it 
appeared that an ER-positive primary tumor generally gives rise to an ER-
positive metastasis, whereas an ER-negative primary tumor gives rise to an 
ER-negative metastasis. Therefore it can be expected that ER assays perfor-
med in the primary tumor can be used to guide endocrine treatment or 
other treatments, when a patient subsequently develops metastatic disease. 
Recently DeSombre and Jensen (1977) reported that the ER value of the primary 
breast tumor predicted response to endocrine treatment much later, at time 
of recurrence. 
In accordance with recent reports of Leclercq et al. (1977) and Hor-
witz and McGuire (1977) it was observed that ER-positive primary breast 
tumors were significantly more frequent PgR-positive than metastatic breast 
tumors. In addition it appeared from the present study that in 4 out of 5 
patients PgR became undetectable during the metastatic period of their 
disease (Table 5.9). These observations suggest that the ability to 
synthesize PgR is lost in dedifferentiating metastasizing tumors. 
Various investigators have studied the influence of the menopausal 
status on steroid hormone receptors. It has consistently been observed that 
tumors from premenopausal patients contain lower F.R values than tumors from 
postmenopausal patients (Wittliff, 1974; McGuire, Carbone and Vollmer, 
1975; Matsumoto and Sugano, 1978; Table 5.4). These lower ER levels may be 
related to the higher levels of circulating endogenous estrogens in these 
patients, which could occupy free cytoplasmic receptor sites and thus 
make them unavailable with the assays used. 
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Therefore several investigators have studied, whether high plasma 
estrogen levels or high concentrations o£ endogenous estrogens in tumor 
cytosols were related to low or negative ER measurements (Maass et al., 1975; 
Fishman et al., 1977; Theve et al., 1978). From these studies it appeared 
that no relationship exists between ER binding and endogenous estrogen 
levels, although in a few patients with very high plasma estradiol levels 
no ER binding was detectable. In fact estradiol levels were higher in 
cytosols from ER-positive tumors, compared to cytosols from ER-negative 
tumors (Fishman et al., 1977; Maynard et al., 1977). Moreover Sakai and 
Saez (1976) showed that the underestimation of cytoplasmic receptor values, 
because of occupation of free receptor sites, is too low to explain the 
observed difference between pre- and postmenopausal patients. However these 
studies do not exclude the possibility that estradiol receptor complexes 
have translocated to the cell nucleus and therefore were no longer detectable 
in the cytoplasmic fraction. Bayard et al. (1978) have reported that in 
human endometrium tissue both estradiol and progesterone total receptor 
concentrations (cytoplasmic + nuclear) were highest in the preovulatory 
phase and were significantly lower in the late secretory phase. The distri-
butions of both receptors between the cytoplasmic and nuclear compartment 
was dependent on the circulating levels of estradiol and progesterone. About 
50% of both receptors were present in the nucleus at the time that these 
steroid hormones were highest during the menstrual cycle. Recently Saez 
et al. (1978) showed that the mean cytoplasmic ER level in human breast 
tumors is also lower at the end of the cycle, but the difference was not 
significant. These investigators suggested that the lower ER values in 
premenopausal women are perhaps due to the fact that the cyclic pro-
gesterone increase limits estrogen stimulation of ER synthesis. This 
suggestion is in agreement with recent findings, which demonstrate that 
progesterone in vivo as well as in vitro can suppress estrogen receptor 
synthesis (Sasaki and Leung, 1975; Hsueh et al., 1975). 
PgR levels, in contrast to ER levels, were not different in pre- and 
postmenopausal patients and the incidence of PgR-positive tumors was also 
similar in both groups of patients (May-Levin et al., 1977; Leclercq et al., 
1977; Saez et al., 1978; McGuire, 1978; Tables 5.3 and 5.4). Remarkably 
May-Levin etal. (1977) and McGuire (1978), as in the present study, observed 
that tumors from postmenopausal patients were more often ER+ PgR- (23-30%) 
than tumors from premenopausal patients (8-12%). 
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Saez et al. (1978) found that no PgR was detectable in human breast tumors 
from 32 premenopausal patients, who had plasma progesterone levels above 
100 ng/100 ml, whereas 15 out of 40 (37%) premenopausal patients with lower 
plasma levels were PgR-positive. It is worth mentioning that in the study 
of Saez et al. (1978) the incidence of ER+ PgR- tumors in premenopausal 
patients was 3 times higher (38%) than in the reports mentioned above (8-12%). 
Several investigators have performed multiple simultaneous ER assays 
and without exception noticed that there are patients, who at the same time 
have ER-positive and ER-negative tumors (Rosen et al., 1977; Kiang and 
Kennedy, 1977; Singhakowinta et al., 1976). In this study 7 out of 8 tumors 
were classified identical. In most studies a similar frequency (85-90%) 
was found. In one report 8 out of 25 (33%) cases were ER-positive at one 
site and ER-negative at another (Webster et al., 1978). It has been suggested 
that this phenomenon may explain why some patients with ER-positive tumors 
failed to respond to endocrine treatment. 
In the present study it appeared that multiple sequential biopsies from 
the same patient generally were both ER-positive or ER-negative. In 84% of 
37 patients from whom at least two sequential biopsies - from the primary 
breast tumor and a metastasis or from different metastatic lesions - have 
been analysed for the presence of ER both tumors were classified identical 
(in 3 patients sequential biopsies were taken once from the primary tumor 
and twice from metastases). In a number of reports (Rosen et al., 1977; 
Leung et al., 1975; Matsumota and Sugano, 1975; Webster et al., 1970) 
differences in ER classification occurred in 11 to 28% of the cases or 
even higher than 50% (Engelsman, 1978). Although in these reports des-
cribed in the literature occasionally a patient with an ER-negative lesion 
subsequently revealed an ER-positive lesion, the more frequent change was 
for a positive lesion to become negative. Because of the possibility that 
the receptor status of a patient has changed during the cause of her 
disease, receptor assays should be performed, whenever possible just prior 
to instituting treatment. Little information is available on quantitative 
ER levels in sequential biopsies. In this study ER levels in most patients 
declined as their disease progressed (Figs. 5.5 and 5.6). Walt et al. (1976) 
showed that in 14 out of 15 patients ER levels substantially declined in 
serial biopsies. In the latter study all patients received endocrine 
treatment and a few also chemotherapy during the interval between the 
receptor assays. 
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Two hypotheses exists to explain that tumors loose receptor activity and 
eventually become ER-negative. First, tumors are composed of dependent 
(ER-positive) and independent (ER-negative) cells. During endocrine therapy 
the growth of dependent cells is inhibited, allowing independent cells to 
become dominant (Sluyser, 1977). Secondly, during the course of this 
disease individual cells become more autonomous and loose the ability to 
produce ER (Singhakowinta et al., 1976). 
In a few patients receptor assays were performed prior and during the 
administration of tamoxifen or ethynylestradiol. During both types of 
therapy ER became undetectable. These findings are in accordance with 
those of Carola et al. (1974), Engelsman (1978) and Singhakowinta et al. 
(1976), who also observed a complete loss of cytoplasmic ER activity during 
antiestrogen and estrogen therapy. It is clear that tissues of patients 
receiving estrogen or antiestrogen therapy are not suitable for receptor 
studies. During ethynylestradiol high PgR levels were observed in the 
tumors of the 3 patients that were studied (Table 5.10). One patient 
responded and the other two failed to respond to this therapy. This obser-
vation indicates that the effects of ethynylestradiol on tumor growth and 
on PgR synthesis were dissociated. There is no conclusive information in 
the literature as to how much time is required for a breast tumor to become 
ER-positive again after discontinuation of estrogen or antiestrogen therapy. 
From the data presented in this study it followed that 12 out of 15 
patients showed ER-positive tumors 4 weeks or later after these treatments 
were stopped (5.6). The remaining 3 patients showed ER-negative tumors 3, 6 
and 8 weeks after discontinuation of ethynylestradiol or tamoxifen therapy. 
The collected results of 8 institutions on a total of 245 patients show 
that measurement of PgR along with ER enhances the ability to select 
patients for endocrine therapy (DeSombre and Jensen, 1977; McGuire^ 1978). 
The response rate of patients, whose tumors contained both receptors was 
74% (70/95), whereas the response rate of patients, whose tumors con-
tained ER but no PgR was only 28% (21/74). Especially the last years the 
importance of quantitative receptor measurement has been recognized. Several 
investigators showed that a positive relation exists between the concentra-
tion of ER binding sites and the response to endocrine treatment (Jensen 
et al., 1975; Heuson et al., 1976; Engelsman, 1978; McGuire, 1978; 
Westerberg et al., 1978). 
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These data are the more impressive if one takes into account that the results 
were expressed in inadequate parameters such as fmoles/g wet tissue or as 
fmoles/mg protein. Since a positive correlation exists between the quantita-
tive ER levels and the presence of PgR (Table 5.7) it is possible that 
quantitative ER levels or PgR measurements identify the same group of 
patients with the highest probability of obtaining a remission to endocrine 
therapy. 
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SUMMARY 
The scope of this investigation of steroid hormone receptors is closely 
connected with the clinical study described by Beex in his concomitant 
thesis. Both studies were designed to obtain further information about the 
relation between steroid hormone receptors and endocrine responsiveness of 
breast carcinoma. 
A brief review of the vast literature on steroid hormone receptors and 
hormone dependency of tumor tissues and the scope of this thesis have been 
presented in Chapter 1. 
Chapter 2 describes the method developed for the determination of 
estradiol and progesterone receptor activity. The multiple point dextran-
coated charcoal assay allows construction of a Scatchard plot even when 
relatively small amounts of tissue (100 mg) are available for analysis. As 
3 3 
the radioactive ligands, H-estradiol was used for ER and H-R5020 for PgR 
assay. 
The criteria used to classify a tumor as receptor-positive were a plot 
with a linear portion and a calculated К value lower than 4 nM. It 
appeared that receptor values were underestimated when the protein content 
of the cytosol was lower than 2 mg per ml. Such cytosols may be falsely 
scored as receptor-negative. The lower limit of sensitivity was about 40 
fmoles per ml cytosol for both the estradiol and progesterone receptor. In 
terms of fmoles per mg of cytosol protein, the lowest values actually 
measured were 5 and 8, respectively. 
From studies regarding the possible interference of plasma proteins 
such as Sex Hormone Binding Globulin with the ER assay, it was concluded that 
such interference, if present, was slight and occurred only when tumors 
showed a relatively low receptor value. The virtual absence of interference 
from plasma proteins, especially SHBG, with the ER assay was confirmed by 
3 . . . . 
using H-moxestrol, a ligand which does not bind to this protein. 
Experiments in which two different radioactive ligands (R5020 and Org 2058) 
were used for the assay of PgR strongly indicated that no serious inter­
ference from plasma proteins or glucocorticoid receptor binding sites 
occurred. 
It is emphasized in the literature that there is a need for intra- and 
inter-laboratory quality control of receptor measurements. 
109 
In the present study, this problem was approached by preparing a lyophilised 
calf uterus powder which was found to be appropriate for such purpose. 
Chapter 3 reports new experimental observations of the endocrine res-
ponsiveness of DMBA rat mammary tumors in relation to quantitative receptor 
values. Essentially all DMBA-tumors contained detectable amounts of ER. The 
ER levels of endocrine responsive tumors were significantly higher than those 
of unresponsive tumors; however, no absolute distinction could be made between 
both groups of tumors on the basis of ER levels. 
It has been hypothesized by McGuire et al. (1975) that for prediction 
of endocrine responsiveness of breast tumors, the progesterone receptor -
being an end product of estrogen action - would be a better marker than the 
estradiol receptor itself. 
The results of this study do not support this hypothesis. Endocrine un-
responsive DMBA-tumors can contain significant amounts of cytoplasmic 
progesterone receptor activity. Furthermore, it was shown that PgR in DMBA-
tumors is under acute control of estradiol. Such control was not res-
tricted to ovarian-dependent tumors, but also was observed in ovarian-inde-
pendent tumors. These observations point to a dissociation between estradiol 
responsiveness and estradiol-induced PgR synthesis. Nevertheless, tumor 
regrowth occurred with estradiol administration in those tumors that had 
relatively high pre-ovariectomy ER and PgR levels. 
In Chapter 4 it was reported that the regression of tumors upon admini-
stration of the antiestrogen tamoxifen appeared to be related with ER levels; 
regressing tumors had higher ER levels than non-regressing tumors. Again, 
however, there was no absolute division between the two groups of tumors. 
Progesterone receptors were detectable in all regressing and in about half of 
the non-regressing tumors. Total absence of detectable PgR occurred only in 
tamoxifen-unresponsivè tumors. Thus, measurement of PgR along with ER 
provides additional although not definitive information with regard to 
this type of endocrine responsiveness. 
Interestingly, during long term (2-3 months) tamoxifen treatment, regressed 
tumors showed spontaneous regrowth and new growing tumors developed. Because 
these tumors did not respond to ovariectomy after tamoxifen withdrawal, 
they can be regarded as autonomous. In these tumors, ER levels were very low 
or undetectable. Remarkably, PgR was not only detectable but still inducible 
by estradiol in most of these autonomous tumors. 
1 10 
This observation is another illustration that hormone independency can 
accompany intact estradiol-inducible PgR synthesis. 
In Chapter 5, data are collected which are of relevance to the inter-
pretation of receptor measurements in human mammary carcinoma. Although ER 
as well as PgR levels of primary and metastatic tumors showed a wide range 
of values, in none of the biopsies of benign tumors or normal breast tissue 
was receptor activity detectable. ER classifications of different tumor spe-
cimens taken from the same patient - whether simultaneously or sequentially, 
from primary tumor to metastasis or from metastasis to metastasis - were 
generally (in 49 of 56 occasions) in agreement. ER became undetectable during 
tamoxifen or ethynylestradiol treatment, which means that receptor analysis 
under such conditions is of little value. Several weeks may be required 
after discontinuation of such therapies before receptor studies are relevant. 
If all of the 388 tumors analysed are considered, 71% were ER-positive. Of 
these ER-positive tumors, 68% contained also PgR, wherewas in only 9% of 
the ER-negative tumors was PgR detectable. Actually, the percentage of 
PgR-positive tumors was positively correlated with the level of ER. These 
findings strongly indicate that in these mammary carcinomas, as in normal 
target tissues and in DMBA-induced rat mammary tumors, the synthesis of 
PgR depends on the action of estrogen. Furthermore, it appeared that the 
frequency of PgR-positive tumors was significantly higher among primary 
than among metastatic tumors. In addition, of the ER-positive primary tumors, 
72% had detectable levels of PgR whereas only 55% of ER-positive metastatic 
tumors contained PgR. These findings indicate that endocrine control 
mechanisms are lost when the tumor cells become more dedifferentiated. 
In line with this assumption were the few observations that PgR became 
undetectable during the metastatic period of the disease. 
From these observations and considerations, it emerges that it is 
likely that progesterone receptor measurements, along with the assay of 
ER, may improve the selection of endocrine responsive tumors. From a 
recent report (McGuire, 1978) in which the clinical correlation data of 
various investigators were collected, it appeared that, indeed, in the 
presence of both ER and PgR the chance of endocrine responsiveness was 
74%. Objective response of patients in which ER was positive, irrespective 
of PgR was 53%. 
1 1 1 
In a small series of patients collected in our institution (Beex et al., 
unpublished observations) ER+ PgR+ tumors apparently showed more objective 
remissions with endocrine therapy than ER+ PgR- tumors. The hypothesis 
of McGuire et al. has thus received sufficient support from these studies 
to warrant continued research in this direction. 
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SAMENVATTING 
Het hier beschreven onderzoek is steeds nauw verbonden geweest met dat 
van internist Beex. Zijn klinische studies zijn verwerkt in een gelijktijdig 
verschenen proefschrift. Het gemeenschappelijke onderwerp is de relatie 
tussen Steroid hormoon receptoren en hormoongevoeligheid van het mammacarci-
noom. 
De zeer omvangrijke literatuur die over dit onderwerp bestaat, is 
summier behandeld in hoofdstuk 1, waarin ook de doelstellingen van het onder-
zoek staan beschreven. 
In hoofdstuk 2 volgt een beschrijving, alsmede een evaluatie, van de 
methodieken die werden ontwikkeld voor de bepaling van oestrogeenreceptoren 
(ER) en progesterorreceptoren (PgR). Voor de bepaling van ER en PgR werden 
3 . . 3 . . . 
H-E respectievelijk H-R5020 gebruikt. Het bleek bij toepassing van deze 
methoden mogelijk om van slechts kleine hoeveelheden tumorweefsel (100 mg) 
uit te gaan terwijl toch elke afzonderlijke receptor bepaling, middels de 
"meerpuntsmeting" op specificiteit kon worden getoetst. De uit de "meerpunts-
meting" geconstrueerde Scatchard curve levert niet alleen informatie over 
de specificiteit maar ook over de onderste gevoeligheidsgrens van de be-
paling. Dit laatste is van groot belang aangezien de beoordeling van een 
tumor als zijnde receptor-positief of receptor-negatief belangrijke konse-
kwenties heeft voor de behandeling van patiënten met een gemetastaseerd 
mammacarcinoom. Blijkens het onderzoek is de gevoeligheid van de bepaling 
mede afhankelijk van de eiwitconcentratie van het tumorhomogenaat. Het 
verdient aanbeveling om bij de uitslag van de receptor analyse de eiwit-
concentratie van het cytosol te vermelden. De gevoeligheid van de methode 
werd bij benadering vastgesteld op 40 fmol per ml cytosol. Uitgedrukt in 
fmol/mg eiwit waren de laagst gemeten receptor concentraties 5 voor ER en 
8 voor PgR. 
Uit de resultaten van studies, waarin de mogelijke interferentie van 
plasma eiwitten zoals het Sex Hormone Binding Globulin (SHBG) met de be-
paling van ER werd bestudeerd, bleek dat deze interferentie, indien aan-
wezig, slechts gering was en alleen optrad in tumoren met een relatief lage 
receptor concentratie. De nagenoeg afwezige interferentie werd bevestigd 
d.m.v. studies, waarbij gebruik werd gemaakt van een ligand met slechts een 
3 
zeer lage affiniteit voor SHBG ( H-moxestrol). 
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Ook de eventueel storende invloed van plasma eiwitten en glucocorticoid 
receptoren op de meting van PgR werd geanalyseerd. Uit de resultaten van 
3 
experimenten, waarbij twee verschillende liganden werden gebruikt ( H-R5020 
3 
en H-Org 2058), bleek niets van een dergelijke storing. 
Het resultaat van een receptor analyse is niet alleen van de gekozen 
methodiek afhankelijk, maar eveneens van een groot aantal vaak nog onbekende 
factoren. Dientengevolge bestaat er behoefte aan een stabiel receptor 
preparaat dat in elke reeks van bepalingen kan worden meegenomen. Op deze 
wijze is een intra- en inter-"assay" variatiecoëfficiënt vast te stellen en 
bovendien kunnen laboratoria onderling hun resultaten vergelijken. Uit het 
beschreven onderzoek is gebleken dat door lyophilisatie van kalfsuterus 
weefsel een dergelijk preparaat kan worden bereid. 
In hoofdstuk 3 staan studies beschreven naar de relatie tussen receptor 
concentraties en de hormoongevoeligheid van door dimethylbenzanthraceen bij 
ratten geïnduceerde mamma tumoren. In nagenoeg alle DMBA-tumoren kon ER 
worden aangetoond. In ovarium-afhankelijke tumoren bleek de concentratie van 
de oestradiolreceptor significant hoger te zijn dan in ovarium-onafhankelijke 
tumoren. Echter beide groepen van tumoren konden niet volledig van elkaar 
onderscheiden worden op basis van de ER concentraties. 
McGuire en medewerkers (1975) hebben als hypothese gesteld dat hormoon-
gevoeligheid van het mammacarcinoom mogelijkerwijs beter gedetecteerd zou 
kunnen worden door meting van de progesteron receptor, als zijnde een eind-
product van oestrogène activiteit. 
De gegevens van dit hoofdstuk geven niet direct steun aan deze hypothese. 
Het bleek, dat ovarium-onafhankelijke tumoren aanzienlijke PgR concentraties 
kunnen bezitten. Bovendien werd aangetoond dat zowel in ovarium-afhankelijke 
als ook in ovarium-onafhankelijke DMBA-tumoren de PgR synthese onder directe 
invloed staat van oestradiol. Deze waarnemingen duiden op een ontkoppeling 
van oestradiol gereguleerde tumorgroei en oestradiol geïnduceerde PgR 
synthese. Niettemin trad tumorhergroei door toediening van oestradiol slechts 
op in tumoren, die vóór de ovariectomie relatief hoge oestradiol en pro-
gesteron receptor concentraties vertoonden. 
Uit de resultaten van hoofdstuk 4 blijkt dat er een relatie bestaat 
tussen tumor regressie, bewerkstelligd door toediening van het antioestrogeen 
tamoxifen en de hoogte van de oestradiol receptor concentratie. De ER con-
centratie was hoger in tumoren die regressie vertoonden dan in tumoren 
waarvan de tumorgroeisnelheid niet-meetbaar veranderde door de toediening 
114 
van tamoxifen. Ook in dit experiment bleek, dat beide groepen van tumoren 
niet volledig van elkaar onderscheiden konden worden, noch op basis van ER 
noch op basis van PgR activiteit. In alle tumoren die regressie vertoonden 
werd PgR activiteit aangetoond, evenals in ongeveer de helft van de tumoren 
waarbij geen teruggang van tumorweefsel optrad. Hieruit blijkt dat het meten 
van PgR naast ER weliswaar additionele, echter geen volledige, informatie 
geeft met betrekking tot dit type van hormoongevoeligheid. 
Tijdens langdurige (2-3 maanden) tamoxifen toediening lieten tumoren, 
waarbij eerder een teruggang van tumorweefsel was opgetreden, spontane her-
groei zien en ontwikkelden zich nieuwe tumoren. Aangezien deze tumoren niet 
reageerden op het verwijderen van de ovaría, nadat de tamoxifen toediening 
gestaakt was, werden deze beschouwd als zijnde autonoom. De ER concentraties 
in deze tumoren waren zeer laag tot niet-meetbaar. Opmerkelijk was dat de 
PgR activiteit, die in de meeste van deze autonome tumoren aantoonbaar was, 
nog steeds geïnduceerd kon worden door oestradiol. Blijkbaar kan hormoon-
onafhankelijkheid samengaan met het intact zijn van het mechanisme waardoor 
oestradiol PgR synthese stimuleert. 
In hoofdstuk 5 zijn gegevens verzameld die van belang geacht kunnen 
worden voor de interpretatie van receptor metingen in humane mammacarci-
nomen. Alhoewel de ER en PgR concentraties in primair en metastatisch tumor-
weefsel een zeer grote spreiding lieten zien, bleek in geen van de ge-
analyseerde biopLen van goedaardig tumorweefsel of normaal borstweefsel 
receptor activiteit aantoonbaar. De ER uitslag van verschillende tumor-
biopten van eenzelfde patient - of de biopsie nu gelijktijdig of op ver-
schillende tijdstippen plaatsvond (eerst in de primaire tumor en ver-
volgens in een métastase òf in twee verschillende metastasen) - was over 
het algemeen (in 49 van de 56 gevallen) identiek. Geconstateerd werd dat de 
ER activiteit tijdens tamoxifen of ethynyloestradiol behandeling daalde tot 
niet-meetbare waarden, hetgeen inhoudt dat receptor analyses onder deze 
condities weinig zinvol zijn. Na het staken van deze therapieën dient 
verscheidene weken gewacht te worden met het nemen van een biopt. 
Van alle 388 geanalyseerde tumoren bleek 71% ER-positief. In 68% van 
de ER-positieve tumoren werd PgR aangetroffen, terwijl het overeenkomstige 
percentage in ER-negatieve tumoren slechts 9% was. Er bleek een positieve 
relatie t2 bestaan tussen het percentage PgR-positieve tumoren en de hoogte 
van de ER concentratie. 
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Deze waarnemingen suggereren dat in humane mammacarcinomen, evenals in normale 
doelwitcellen en in DMBA-geinduceerde mammatumoren, de PgR synthese onder 
controle van oestradiol staat. Bovendien bleek, dat in primaire tumoren vaker 
PgR werd aangetroffen dan in metastasen. Ook werd vastgesteld dat in 72% van 
de ER-positieve primaire tumoren PgR aanwezig was, terwijl slechts 55% van de 
ER-positieve metastasen PgR bevatten. Deze bevindingen duiden erop dat 
endocriene regulatie systemen verloren gaan wanneer tumorcellen deditferen-
tiëren. De waarneming dat de PgR activiteit in enkele patiënten daalde tot 
niet-meetbare waarden tijdens het proces van tumor metastasering is hiermee 
in overeenstemming. 
Deze waarnemingen en beschouwingen maken het aannemelijk dat het meten 
van receptoren voor progesteron naast die voor oestradiol een bijdrage kan 
leveren aan de selectie van hormoongevoelige tumoren. Uit een recente pu-
blicatie (McGuire, 1978), waarin de klinische gegevens van verschillende 
onderzoekers zijn verzameld, blijkt dat 74% van de patiënten met tumoren, 
waarin beide receptoren aanwezig zijn, gunstig reageerden op endocriene 
maatregelen. Wanneer wordt afgezien .van de aan- of afwezigheid van PgR 
blijkt slechts 53% van de patiënten met ER-positieve tumoren een objectieve 
remissie te vertonen. 
Uit de klinische follow-up van een zeer beperkte groep van patiënten 
(zie proefschrift Beex, 1979) behandeld in het Radboud Ziekenhuis blijkt, 
dat objectieve remissies bij patiënten met ER+ PgR+ tumoren vaker voorkomen 
dan bij patiënten met ER+ PgR- tumoren. Het onderzoek hiernaar wordt voort-
gezet. 
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